

Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) EP 0 555 205 B1

(12)

## EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention  
of the grant of the patent:  
29.11.2000 Bulletin 2000/48

(21) Application number: 90903253.4

(22) Date of filing: 30.01.1990

(51) Int. Cl.<sup>7</sup>: C07K 1/22, C07K 14/00,  
C07K 7/06, C07K 7/08,  
C12N 5/00, C12N 15/00,  
G01N 33/536

(86) International application number:  
PCT/US90/00418

(87) International publication number:  
WO 90/08771 (09.08.1990 Gazette 1990/19)

(54) DNA ENCODING A GROWTH FACTOR SPECIFIC FOR EPITHELIAL CELLS  
DNS KODIEREND FÜR EINEN FÜR EPITHELZELLEN SPEZIFISCHEN WACHSTUMSFAKTOR  
ADN CODANT UN FACTEUR DE CROISSANCE SPECIFIQUE CONTRE DES CELLULES  
EPITHELIALES

(84) Designated Contracting States:  
AT BE CH DE DK ES FR GB IT LI LU NL SE

(30) Priority: 31.01.1989 US 304281

(43) Date of publication of application:  
18.08.1993 Bulletin 1993/33

(60) Divisional application:  
00103140.0 / 1 016 716

(73) Proprietors:  
• RUBIN, Jeffrey S  
Rockville, MD 20851 (US)  
• FINCH, Paul W  
Bethesda, MD 20814 (US)  
• AARONSON, Stuart A  
Great Falls, VA 22066 (US)

(72) Inventors:  
• RUBIN, Jeffrey S  
Rockville, MD 20851 (US)  
• FINCH, Paul W  
Bethesda, MD 20814 (US)  
• AARONSON, Stuart A  
Great Falls, VA 22066 (US)

(74) Representative:  
Grünecker, Kinkeldey,  
Stockmair & Schwanhäusser  
Anwaltssozietät  
Maximilianstrasse 58  
80538 München (DE)

(56) References cited:  
US-A- 4 444 760 US-A- 4 743 679

- PROCEEDINGS OF THE NATL. ACADEMY OF SCIENCES USA, vol. 86, February 1989, Washington, DC (US); J.S. RUBIN et al., pp. 802-806
- SCIENCE, vol. 245, 18 August 1989; P.W. FINCH et al., pp. 752-755
- THE EMBO JOURNAL, vol. 5, no. 5; MOORE, pp. 919-924
- NUCLEIC ACIDS RESEARCH, vol. 17(F), 11 April 1989; GOODRICH, p. 286f
- PROCEEDINGS OF THE NATL. ACADEMY OF SCIENCES USA, vol. 82, October 1985, Washington, DC (US); ESCH, pp. 6507-6511
- CELL, vol. 38, August 1984; DERYNCK, pp. 287-297
- IMMUNOLOGY, 1978, 3rd ed.; BARRETT, pp. 110-113

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 0 555 205 B1

## Description

### FIELD OF THE INVENTION

[0001] The present invention relates to growth factors, particularly to isolation of a polypeptide growth factor similar to a family of factors including known fibroblast growth factors (FGFs). This invention also relates to construction of complementary DNA (cDNA) segments from messenger RNA (mRNA) encoding the novel growth factor. Further, this invention pertains to synthesis of products of such DNA segments by recombinant cells, and to the manufacture and use of certain other novel products enabled by the identification and cloning of DNAs encoding this growth factor.

### ABBREVIATIONS USED IN THIS APPLICATION

[0002]

aFGF	acidic fibroblast growth factor
bFGF	basic fibroblast growth factor
EGF	epidermal growth factor
HSAC	heparin-Sepharose affinity chromatography
kb	kilobases
kDa	kilodaltons
KGF	keratinocyte growth factor
NaDodSO <sub>4</sub> /PAGE	Sodium dodecylsulphate (SDS)/polyacrylamide gel electrophoresis
RP-HPLC	reversed-phase high performance liquid chromatography
TGF $\alpha$	transforming growth factor $\alpha$

### BACKGROUND OF THE INVENTION

[0003] Growth factors are important mediators of intercellular communication. These potent molecules are generally released by one cell type and act to influence proliferation of other cell types (see reference I-1 in Experimental Section I, below). Interest in growth factors has been heightened by evidence of their potential involvement in neoplasia (reference II-2 in Experimental Section II, below). The *v-sis* transforming gene of simian sarcoma virus encodes a protein that is homologous to the B chain of platelet-derived growth factor (I-1, I-2). Moreover, a number of oncogenes are homologues of genes encoding growth factor receptors (I-1). Thus, increased understanding of growth factors and their receptor-mediated signal transduction pathways is likely to provide insights into mechanisms of both normal and malignant cell growth.

[0004] One known family of growth factors affecting connective tissue cells includes acidic fibroblast growth factor (aFGF), basic fibroblast growth factor (bFGF), and the related products of the *hst* and *int-2* oncogenes.

[0005] Further, it is known that some growth factors,

including the following, have heparin-binding properties: aFGF (I-20, I-21); bFGF (I-19, I-20); granulocyte/macrophage colony stimulating factor (I-1); and interleukin 3 (I-1). Each of these polypeptide factors is produced by stromal cells (I-1, I-2, I-25). Such factors appear to be deposited in the extracellular matrix, or on proteoglycans coating the stromal cell surface (I-1, I-25). It has been postulated that their storage, release and contact with specific target cells are regulated by this interaction (I-25, I-28).

[0006] It is widely recognized, however, that the vast majority of human malignancies are derived from epithelial tissues (I-5). Effectors of epithelial cell proliferation derived from mesenchymal tissues have been described (I-1, I-2, I-3), however, their molecular identities and structures have not been elucidated.

[0007] In light of this dearth of knowledge about such mesenchymal growth factors affecting epithelial cells, it is apparent that there has been a need for methods and compositions and bioassays which would provide an improved knowledge and analysis of mechanisms of regulation of epithelial cell proliferation, and, ultimately, a need for novel diagnostics and therapies based on the factors involved therein.

[0008] This invention contemplates the application of methods of protein isolation and recombinant DNA technologies to fulfill such needs and to develop means for producing protein factors of mesenchymal origin, which appear to be related to epithelial cell proliferation processes and which could not be produced otherwise. This invention also contemplates the application of the molecular mechanisms of these factors related to epithelial cell growth processes.

### SUMMARY OF THE INVENTION

[0009] The present invention relates to developments of protein isolation and recombinant DNA technologies, which include production of novel growth factor proteins affecting epithelial cells, free of other peptide factors. Novel DNA segments and bioassay methods are also included.

[0010] The present invention in particular relates to a novel protein having structural and/or functional characteristics of a known family of growth factors which includes acidic fibroblast growth factor (aFGF), basic fibroblast growth factor (bFGF) and the related products of the *hst* and *int-2* oncogenes. This new member of the FGF polypeptide family retains the heparin-binding properties of the FGFs but has evolved a unique target cell specificity. This growth factor appears to be specific for epithelial cells and is particularly active on keratinocytes. Therefore, this novel factor has been designated "keratinocyte growth factor" (KGF). Notwithstanding its lack of activity on fibroblasts, since it is the sixth known member of the FGF polypeptide family, KGF may also be referred to as FGF-6. According to the present invention the term "KGF or KGF-like proteins" means an iso-

CRTQWYLRIKRGKVKGTQEMKN  
 NYNIMEIRTVAVGIVAIGVESEF  
 YLAMNKEGKLYAKKECNEDCNFK  
 ELILENHNTYASAKWTHNGGEM  
 FVALNQKGIPVRGKKTKEQKTA  
 HFLPMAIT,

wherein said segment has mitogenic activity for a keratinocyte cell, and wherein said segment may further include methionine at the amino terminus.

[0022] In a still preferred embodiment the KGF protein has a specific activity of at least about  $3.4 \times 10^4$  units per milligram of protein, where one unit of activity is defined as that amount which causes half of the maximal possible stimulation of DNA synthesis in BALB/MK keratinocyte cells.

[0023] In a still preferred embodiment the KGF protein comprises Met at the amino terminus.

[0024] Accordingly, this invention relates, in part, to purified KGF or KGF-like proteins and methods for preparing these proteins. Such purified factors may be made by cultivation of human cells which naturally secrete these proteins and application of isolation methods according to the practice of this invention. These proteins can be used for biochemical and biological studies leading, for example, to isolation of DNA segments encoding KGF or KGF-like polypeptides.

[0025] The present invention also relates to such DNA segments which encode KGF or KGF-like proteins. In a principal embodiment, the present invention relates to DNA segments, which encode KGF-related products, consisting of: human cDNA clones 32 or 49, derived from polyadenylated RNA extracted from the human embryonic lung fibroblast cell line M426; recombinants and mutants of these clones; and related DNA segments which can be detected by hybridization to any of the above human DNA segments, which related segments encode KGF-like proteins or portions thereof.

[0026] In the practice of one embodiment of this invention, the DNA segments of the invention are capable of being expressed in suitable host cells, thereby producing KGF or KGF-like proteins. The invention also relates to mRNAs produced as the result of transcription of the sense strands of the DNA segments of this invention.

[0027] In another embodiment, the invention relates to a recombinant DNA molecule comprising a vector and a DNA of the present invention. These recombinant molecules are exemplified by molecules comprising a KGF cDNA and any of the following vector DNAs: a bacteriophage  $\lambda$  cloning vector (exemplified by  $\lambda$ pCEV9); a DNA sequencing plasmid vector (e.g., a pUC variant); a bacterial gene expression vector (e.g., pKK233-2); or a mammalian gene expression vector (such as pMMT).

[0028] In still another embodiment, the invention comprises a cell, preferably a mammalian cell, comprising a vector with a DNA of the invention. Further, the invention comprises cells, including insect cells, yeast

cells and bacterial cells such as those of *Escherichia coli* and *B. subtilis*, comprising a vector with DNAs of the invention. According to another embodiment of this aspect of the invention, the transforming DNA is capable of being expressed in the cell, thereby increasing in the cell the amount of KGF or KGF-like protein encoded by this DNA.

[0029] The primary KGF translation product predicted from its cDNA sequence contains an N-terminal hydrophobic region which likely serves as a signal sequence for secretion and which is not present in the mature KGF molecule. In a most preferred embodiment of the gene expression aspect of the invention, the cell transformed by the DNA of the invention secretes the protein encoded by that DNA in the (truncated) form that is secreted by human embryonic lung fibroblast cells.

[0030] Still further, this invention contemplates KGF or KGF-like proteins produced by expression of a DNA of the invention, or by translation of an RNA of the invention. Preferably, these proteins will be of the secreted form (i.e., lacking an apparent signal sequence). These protein factors can be used for functional studies, and can be purified for additional structural and functional analyses, such as qualitative and quantitative receptor binding assays.

[0031] Moreover, the ability to produce large quantities of this novel growth factor by recombinant techniques will allow testing of its clinical applicability in situations where specific stimulation of growth of epithelial cells is of particular importance. Accordingly, this invention includes pharmaceutical compositions comprising KGF or KGF-like polypeptides for use in the treatment of such conditions, including, for example, healing of wounds due to burns or stimulation of transplanted corneal tissue.

[0032] According to this embodiment of the invention, the novel KGF-like proteins will be protein products of "unmodified" DNAs and mRNAs of the invention, or will be modified or genetically engineered protein products. As a result of engineered mutations in the DNA sequences, modified KGF-like proteins will have one or more differences in amino acid sequence from the corresponding naturally occurring "wild-type" proteins. According to one embodiment of this aspect of this invention, the modified KGF-like proteins will include "chimeric" molecules comprising a KGF and at least one other member of the FGF peptide family.

[0033] Ultimately, given results of analogous successful approaches with other peptide factors having similar properties, development of such chimeric KGF-like polypeptides should lead to superior, "second generation" forms of KGF-like peptides for clinical purposes. These modified KGF-like products might be smaller, more stable, more potent, and/or easier or less expensive to produce, for example.

[0034] According to another embodiment an invitro method of stimulating epithelial cells is provided comprising adding an amount of the composition comprising

KGF protein or chimeric protein sufficient to stimulate epithelial cell growth.

[0035] This invention further comprises novel bioassay methods for determining expression in human cells of the mRNAs and proteins produced from the genes related to DNA segments of the invention. According to one such embodiment, DNAs of this invention may be used as probes to determine steady state levels or kinetics of induction of related mRNAs. The availability of the KGF-related cDNA clones makes it possible to determine whether abnormal expression of this growth factor is involved in clinical conditions characterized by excessive epithelial cell growth, including dysplasia and neoplasia (e.g., psoriasis, or malignant or benign epithelial tumors).

[0036] This invention also contemplates novel antibodies made against a peptide encoded by a DNA segment of the invention. In this embodiment of the invention, the antibodies are monoclonal or polyclonal in origin, and are generated using KGF-related polypeptides from natural, recombinant or synthetic chemistry sources.

[0037] The antibodies of this invention bind specifically to KGF or a KGF-like protein which includes the sequence of such peptide, preferably when that protein is in its native (biologically active) conformation. These antibodies can be used for detection or purification of the KGF or antibodies can be used for detection or purification of the KGF or KGF-like protein factors. In a most preferred embodiment of this aspect of the invention, the antibodies will neutralize the growth promoting activity of KGF, thereby enabling mechanistic studies and, ultimately, therapy for clinical conditions involving excessive levels of KGF.

#### BRIEF DESCRIPTION OF THE DRAWINGS

[0038] Fig. 1-1 depicts results of heparin-Sepharose affinity chromatography of conditioned medium from M426 human embryonic fibroblasts showing that greater than 90% of the mitogenic activity for mouse keratinocytes (BALB/MK) eluted with 0.6 M NaCl. Approximately 150 ml of ultrafiltration retentate derived from liters of M426 conditioned medium were loaded onto a heparin-Sepharose column (6 ml bed volume) in 1 hr. After washing the column with 150 ml of the equilibration buffer, 20 mM Tris-HCl, pH 7.5/0.3M NaCl, the retained protein (<5% of the total protein in the retentate) was eluted with a modified linear gradient of increasing NaCl concentration. Fraction size was 3.8 ml and flow rate during gradient elution was 108 ml/hr. Two  $\mu$ l of the indicated fractions were transferred to microtiter wells containing a final volume of 0.2 ml for assay of  $^3$ H-thymidine incorporation in BALB/MK cells as described in the Methods.

[0039] Fig. 1-2 illustrates results of further purification of the mitogen from human fibroblasts using HPLC with and adsorptive matrix. Panel (A) shows the profile

on reversed-phase ( $C_4$ ) HPLC of BALB/MK mitogenic activity. Panel (B) presents electrophoretic (NaDodSO<sub>4</sub>/PAGE) analysis of selected fractions from the  $C_4$  chromatography shown in panel A, demonstrating that the peak HPLC fractions contained a single band on the silver stained gel. Panel (C) is a bar graph of DNA synthesis in BALB/MK cells triggered by the fractions analyzed in Panel B, showing that the relative mitogenic activity correlated well with the intensity of the protein band across the activity profile.

[0040] (A) Reversed-phase  $C_4$ HPLC of BALB/MK mitogenic activity. Active fractions eluted from heparin-Sepharose with 0.6M NaCl were processed with the Centricon -10 and loaded directly onto a  $C_4$  Vydac column (4.6 x 250 mm) which had been equilibrated in 0.1% trifluoroacetic acid/20% acetonitrile (ACN). After washing the column with 4 ml of equilibration buffer, the sample was eluted with a modified linear gradient of increasing % ACN. Fraction size was 0.2 ml and flow rate was 0.5 ml/min. Aliquots for the assay of  $^3$ H-thymidine incorporation in BALB/MK cells were promptly diluted 10-fold with 50  $\mu$ g/ml bovine serum albumin/20 mM Tris-HCl, pH 7.5, and tested at a final dilution of 200-fold. (B) NaDodSO<sub>4</sub>/PAGE analysis of selected fractions from the  $C_4$  chromatography shown in panel A. Half of each fraction was dried, redissolved in NaDodSO<sub>4</sub>/2-mercaptoethanol, heat denatured and electrophoresed in a 14% polyacrylamide gel which was subsequently stained with silver. The position of each molecular weight marker (mass in kDa) is indicated by an arrow. (C) DNA synthesis in BALB/MK cells triggered by the fractions analyzed in Panel B. Activity is expressed as the fold stimulation over background which was 100 cpm.

[0041] Fig. 1-3 presents an alternative purification step to RP-HPLC, using sieving chromatography with a (TSK G3000SW GlasPac) column run in aqueous solution near physiologic pH, which resulted in a major peak of mitogenic activity in the BALB/MK bioassay.

[0042] Molecular sieving HPLC (TSK 3000SW) chromatography of the BALB/MK mitogenic activity. Approximately 50  $\mu$ l of a Centricon-processed, 0.6M NaCl pool from HSAC were loaded onto a LKB GlasPac TSK G3000SW column (8 x 300 mm), previously equilibrated in 20 mM Tris-HCl, pH 6.8/0.5M NaCl, and eluted as 0.2 ml fractions at a flow rate of 0.4 ml/min. Aliquots of 2  $\mu$ l were transferred to microtiter wells containing a final volume of 0.2 ml for assay of  $^3$ H-thymidine incorporation in BALB/MK cells. The elution positions of molecular weight markers (mass in kDa) were as indicated by the arrows.

[0043] Fig. 1-4 illustrates a comparison of BALB/MK DNA synthesis in response to TSK-purified mitogen and other growth factors.

[0044] Comparison of BALB/MK DNA synthesis in response to TSK-purified mitogen and other growth factors. Incorporation of  $^3$ H-thymidine into trichloroacetic acid-insoluble DNA, expressed as fold stimulation over

background, was measured as a function of the concentration of the indicated growth factors. Background values with no sample added were 150 cpm. The results represent mean values of two independent experiments. Replicates in each experiment were within 10% of mean values. TSK-purified mitogen,  $\bullet$ — $\bullet$ ; EGF,  $\Delta$ — $\Delta$ ; aFGF,  $\bullet$ — $\bullet$ ; bFGF,  $\circ$ — $\circ$ .

[0045] Fig. 1-5 shows comparisons of growth of BALB/MK cells in a chemically defined medium in response to different combinations of growth factors.

[0046] Comparative growth of BALB/MK cells in a chemically defined medium in response to different combinations of growth factors. Cultures were plated at a density of  $2.5 \times 10^4$  cells per dish on 35 mm Petri dishes precoated with poly-D-lysine/fibronectin in a 1:1 mixture of Eagle's minimal essential medium and Ham's F12 medium supplemented with transferrin,  $\text{Na}_2\text{SeO}_3$ , ethanolamine and the growth factors indicated below. After 10 days, the plates were fixed and stained with Giemsa. Key: a) no growth factor; b) EGF alone; c) insulin alone; d) KGF alone; e) EGF + insulin. Final concentrations of the growth factors were as follows: EGF, 20 ng/ml; insulin, 10  $\mu\text{g}/\text{ml}$ ; and KGF, 40 ng/ml.

[0047] Table 1-1 summarizes the results from various purification steps, documenting that sieving chromatography provided a far better recovery of activity than the adsorptive RP-HPLC approach.

[0048] Recoveries were calculated by assuming that all of the mitogenic activity in the starting material was due to the isolated factor.

\* One unit of activity is defined as half of the maximal stimulation of thymidine incorporation induced by TSK-purified factor in the BALB/MK bioassay, in which approximately 3 ng of the TSK-purified factor stimulated 1 unit of activity.

<sup>a</sup> Protein was estimated by using the Bradford reagent from BioRad (1-23).

<sup>b</sup> Protein was estimated by using

$$\lambda_{214}^{1\%} = 140.$$

Table 1-2 recapitulates data on the target cell specificities of various growth factors, demonstrating that the newly isolated factor exhibited a strong mitogenic effect on keratinocytes (BALB/MK) and, in striking contrast, had no detectable effects on fibroblasts or human saphenous vein endothelial cells. Comparison of maximal thymidine incorporation stimulated by KGF and other growth factors in a variety of cell lines, expressed as fold stimulation over background. This data represents a summary of four different experiments.

\* Maximal stimulation by aFGF required the presence of heparin (Sigma), 20  $\mu\text{g}/\text{ml}$ .

n.d. = not determined.

[0049] Fig. 11-1 presents the nucleotide sequence and deduced amino acid sequence of KGF cDNA, as well as identification of RNAs transcribed from the KGF gene. Panel (A) outlines a schematic representation of human KGF cDNA clones. Panel (B) documents the KGF cDNA nucleotide and predicted amino acid sequences. (C) Identification of RNA transcripts of KGF genes by Northern blot analysis.

[0050] Nucleotide sequence and deduced amino acid sequence of KGF cDNA, and identification of KGF gene transcripts. (A) Schematic representation of human KGF cDNA clones. Overlapping pCEV9 clones 32 and 49, used in sequence determination, are shown above a diagram of the complete structure in which untranslated regions are depicted by a line and the coding sequence is boxed. The hatched region denotes sequences of the signal peptide and the open region of the mature protein. Selected restriction sites are indicated. (B) KGF cDNA nucleotide and predicted amino acid sequences. Nucleotides are numbered on the right; amino acids are numbered throughout. The N-terminal peptide sequence derived from purified KGF is underlined. The hydrophobic N-terminal domain is italicized. The potential asparagine-linked glycosylation site is overlined. The variant polyadenylation signals, AATTA and AATACA, close to the 3' end of the RNA, are boxed. (C) Identification of KGF mRNAs by Northern blot analysis. Lanes a and c, poly(A)-selected M426 RNA; lane d, total cellular M426 RNA. Filters were hybridized with a  $^{32}\text{P}$ -labeled 695 bp *Bam*HI/*Bcl*I fragment from clone 32 (Probe A, Fig. 11-1A), lanes a and b, or a 541 bp *Apa*I/*Eco*RI fragment from clone 49 (Probe B, Fig. 11-1A), lanes c and d.

[0051] Fig. 11-2 illustrates the topological comparison of the FGF family of related molecules, including KGF, with emphasis on the two protein domains that share high homology, the putative signal peptide sequences, and the two conserved cysteine residues.

[0052] Topological comparison of the FGF family of related molecules. The two protein domains that share high homology are shown by shaded boxes. Hatched boxes indicate putative signal peptide sequences. The positions of two conserved cysteine residues (C) are shown.

[0053] Fig. 11-3 shows (Northern blot) analyses of expression of KGF-related mRNA in selected normal human cell lines and tissues, revealing that a single 2.4 kb transcript was present in RNA from human embryonic lung fibroblasts and from adult skin fibroblasts, while no transcript was detected in the (B5/589) epithelial or (HA83) glial cell lines, or in primary cultures of human saphenous vein endothelial cells.

[0054] Northern blot analysis of KGF mRNA in nor-

mal human cell lines and tissues, and comparison with mRNA expression of other growth factors with known activity on epithelial cells. Total cellular RNAs were isolated by cesium trifluoro-acetate gradient centrifugation. 10 µg of RNA were denatured and electrophoresed in 1% formaldehyde gels. Following mild alkali denaturation (50 mM NaOH for 30'), RNA was transferred to nitrocellulose filters using 1 M ammonium acetate as a convectant. Filters were hybridized to a <sup>32</sup>P-labelled cDNA probe containing the 647bp *Eco*RI fragment from the 5' end of the KGF coding sequence (A) or similar probes from the other growth factor DNAs. The following human cell types were used: squamous cell carcinomas (A253, A388 and A431); mammary epithelial cells (S6 and R1); keratinocytes immortalized with Ad12-SV40; primary human keratinocytes; neonatal foreskin fibroblasts, AG1523; adult skin fibroblasts (501T); and embryonic lung fibroblasts (WI-38 and M426).

[0055] Table II-1 summarizes a comparison of the effect of heparin on KGF mitogenic activity with effects on other growth factors, showing that thymidine incorporation into DNA by BALB/MK cells in response to KGF was inhibited by heparin, in contrast, to the activities of both aFGF and bFGF which were increased by the same treatment.

[0056] Cells were plated in microtiter plates, grown to confluence in serum containing media and then placed in a serum-free medium for 24-72 hr prior to sample addition. Mitogenesis assays were performed as described (see Experimental Section I, above and II-3). Where indicated, heparin was included in the culture media at a final concentration of 20 µg/ml. The concentration of all the growth factors was 50 ng/ml. The results represent fold stimulation of <sup>3</sup>H-thymidine incorporation in the indicated assay cell in the presence (+) or absence (-) of heparin. Each value represents the mean result from two independent experiments in which each point, in turn, represents the mean value of duplicate analyses.

#### DESCRIPTION OF SPECIFIC EMBODIMENTS

[0057] This invention relates, in part, to purified KGF or KGF-like proteins as defined above and methods for preparing these proteins. A principal embodiment of this aspect of this invention relates to homogeneous KGF characterized by an apparent molecular weight of about 28 kDa based on migration in NaDodSO<sub>4</sub>/PAGE, movement as a single peak on reversed-phase high performance liquid chromatography, and a specific activity of at least about 3.4 x 10<sup>4</sup> units per milligram, and preferably at least about 3.2 x 10<sup>5</sup> units per milligram, where one unit of activity is defined as that amount which causes half of the maximal possible stimulation of DNA synthesis in certain epithelial (keratinocyte) cells under standard assay conditions outlined below.

[0058] To identify novel growth factors specific for

epithelial cell types, a clonal BALB/c mouse keratinocyte cell line, designated BALB/MK (I-6) was employed as an indicator cell to detect such factors. These cells are dependent for their growth upon an exogenous source of an epithelial cell mitogen even in medium containing serum (I-6). The development of chemically defined medium for these cells has made it possible to demonstrate that two major mitogenic pathways are required for BALB/MK proliferation. One involves insulin-like growth factor I (or insulin at high concentration) and the other is satisfied by epidermal growth factor (EGF), transforming growth factor α (TGFα), acidic fibroblast growth factor (aFGF) or basic fibroblast growth factor (bFGF) (I-7).

[0059] By using BALB/MK as the prototypical epithelial cell line and NIH/3T3 as its fibroblast counterpart, conditioned media from various human cell lines were assayed for new epithelial cell-specific mitogens. These bioassays of this invention enabled the purification to homogeneity of one such novel growth factor, released by a human embryonic lung fibroblast line, and designated herein as keratinocyte growth factor (KGF).

[0060] In brief, the bioassay for KGF-like activity under standard conditions comprises the following steps:

- (i) Mouse keratinocytes (BALB/MK cells) are grown in culture to confluency and then maintained for 24-72 hr in serum-free medium;
- (ii) Following addition of test samples, stimulation of DNA synthesis is determined by incorporation of <sup>3</sup>H-thymidine into acid-precipitable DNA.

[0061] To determine the cell target specificity of a mitogenic growth factor, the DNA synthesis stimulation, expressed as ratio of stimulated synthesis over background incorporation of thymidine in the absence of added test sample, can be compared to analogous stimulation observed in cells other than keratinocytes under the same assay conditions. In such comparisons, KGF mitogenic activity will exhibit marked specificity for the keratinocytes as opposed to fibroblasts (at least about 500-fold greater stimulation) and lesser but significant (at least about 50-fold) greater activity on keratinocytes than on other exemplary epithelial cell types (see Table I-2 for further data, and Materials and Methods in Experimental Section I for details of the standard conditions of the bioassay).

[0062] By employing a method of KGF production involving culturing cells and isolating mitogenic activity, which method comprises ultrafiltration, heparin-Sepharose affinity chromatography (HSAC) and adsorptive reversed-phase high performance liquid chromatography (RP-HPLC) or, alternatively, molecular sieving HPLC (TSK-HPLC), according to the present invention, a quantity was isolated sufficient to permit detailed characterization of the physical and biological properties of this molecule.

[0063] To summarize, the method for production of KGF from producing cells such as M426 human embryonic fibroblasts (I-8), for example, comprises the following steps:

- (i) Preparation of conditioned media (e.g., 10 liters) using monolayer cultures cycled from serum-containing to serum-free medium and storing the serum-free harvest at -70°C until further use;
- (ii) Concentration by ultrafiltration using membranes having a 10 kDa molecular weight cutoff in several successive steps with intervening dilution in buffer (to facilitate removal of low molecular weight materials), followed by optional storage at -70°C;
- (iii) Affinity chromatography on heparin attached to a polymeric support (e.g., Sepharose) with elution by a gradient of increasing NaCl concentration;
- (iv) Concentration by a factor of at least ten- to twenty-fold with small scale ultrafiltration devices with a 10 kDa molecular weight cutoff (e.g., a Centricon-10 microconcentrator from Amicon) and storage at -70°C.

The next step of the purification process comprises either step (v) or, alternatively, step (vi), as follows:

- (v) Reversed-phase HPLC of active fractions (0.6 M NaCl pool) from the previous HSAC step in organic solvent systems; or,
- (vi) Molecular sieve HPLC (e.g., on a TSK-G3000SW Glas-Pac Column from LKB) in aqueous buffer at near physiological pH (e.g., Tris-HCl, pH 6.8/0.5M NaCl) followed by storage at -70°C.

[0064] A preparation made by the TSK step (vi) was almost as pure as one obtained from RP-HPLC, as judged by silver-stained NaDodSO<sub>4</sub>/PAGE (data not shown); but the TSK approach provided a far better recovery of activity (Table I-1). Further, the TSK-purified material had a higher specific activity than the RP-HPLC material. KGF prepared by the TSK procedure above stimulated DNA synthesis in epithelial cells at sub-nanomolar concentrations, but failed to induce any thymidine incorporation into DNA of fibroblasts or endothelial cells at comparable or higher concentrations (up to 5 nM). The activity was sensitive to acid, heat and solvents used in the RP-HPLC step. (See Experimental Section I for data on sensitivities and further details of the production method.)

[0065] Using standard methodology well known in the art, an unambiguous amino acid sequence was determined for positions 2-13 from the amino terminus of the purified KGF, as follows: Asn-Asp-Met-Thr-Pro-Glu-Gln-Met-Ala-Thr-Asn-Val (see Experimental Section I).

[0066] The present invention also includes DNA segments encoding KGF and KGF-like polypeptides. The DNAs of this invention are exemplified by DNAs referred to herein as: human cDNA clones 32 and 49

derived from polyadenylated RNA extracted from the human embryonic lung fibroblast cell line M426; recombinants and mutants of these clones; and related DNA segments which can be detected by hybridization to these DNA segments.

[0067] As described in Experimental Section II, to search for cDNA clones corresponding to the known portion of the KGF amino acid sequence, two pools of oligonucleotide probes were generated based upon all possible nucleotide sequences encoding the nine-amino acid sequence, Asn-Asp-Met-Thr-Pro-Glu-Gln-Met-Ala. A cDNA library was constructed in a cDNA cloning vector,  $\lambda$ pCEV9, using polyadenylated RNA extracted from the human embryonic lung fibroblast cell line M426 which was the initial source of the growth factor. Screening of the library ( $9 \times 10^5$  plaques) with the <sup>32</sup>P-labelled oligonucleotides identified 88 plaques which hybridized to both probes.

[0068] Of 10 plaque-purified clones that were analyzed, one, designated clone 49, had a cDNA insert of 3.5 kb, while the rest had inserts ranging from 1.8 kb to 2.1 kb. Analysis of the smaller clones revealed several common restriction sites, and sequencing of a representative smaller clone, designated clone 32, along with clone 49, demonstrated that they were overlapping cDNAs (Fig II-1A). Alignment of the two cDNAs established a continuous sequence of 3.85 kb containing the complete KGF coding sequence. The sense strand DNA nucleotide sequence, and the predicted primary protein sequence encoded, are shown for the full-length composite KGF cDNA sequence in Fig. II-1B.

[0069] These DNAs, cDNA clones 32 and 49, as well as recombinant forms of these segments comprising the complete KGF coding sequence, are most preferred DNAs of this invention.

[0070] From the cDNA sequence, it is apparent that the primary KGF and *hst* translation products contain hydrophobic N-terminal regions which likely serve as signal sequences, based on similarity to such sequences in a variety of other proteins. Accordingly, this N-terminal domain is not present in the purified mature KGF molecule which is secreted by human embryonic fibroblasts.

[0071] Furthermore, KGF shares with all other members of the FGF family two major regions of homology, spanning amino acids 65-156 and 162-189 in the predicted KGF sequence, which are separated by short, nonhomologous series of amino acids of various lengths in the different family members. The sequence of the purified form of KGF contains five cysteine residues, two of which are conserved throughout the family of FGF related proteins. Five pairs of basic residues occur throughout the KGF sequence. This same pattern has been observed in other FGF family members.

[0072] It should be obvious to one skilled in the art that, by using the DNAs and RNAs of this invention in hybridization methods (such as Southern blot analyses of genomic human DNAs), especially the most pre-



ferred DNAs listed herein above, without undue experimentation, it is possible to screen genomic or cDNA libraries to find other KGF-like DNAs which fall within the scope of this invention. Furthermore, by so using DNAs of this invention, genetic markers associated with the KGF gene, such as restriction fragment length polymorphisms (RFLPs), may be identified and associated with inherited clinical conditions involving this or other nearby genes.

[0073] This invention also includes modified forms of KGF DNAs. According to a chief embodiment of this aspect of the invention, such modified DNAs encode KGF-like proteins comprising a KGF protein and at least one other member of the FGF peptide family. Thus, for example, since there is no significant N-terminal homology between the secreted form of KGF and analogous positions in other FGF-related proteins, polypeptides with novel structural and functional properties may be created by grafting DNA segments encoding the distinct N-terminal segments of another polypeptide in the FGF family onto a KGF DNA segment in place of its usual NH<sub>2</sub>-terminal sequence.

[0074] The polypeptide chimeras produced by such modified DNAs are useful for determining whether the KGF NH<sub>2</sub>-terminal domain is sufficient to account for its unique target cell specificity. Studies on chimeras should also provide insights into which domains contribute the different effects of heparin on their biologic activities.

[0075] Indeed, the utility of this approach has already been confirmed by the successful engineering and expression of a chimeric molecule in which about 40 amino acids from the NH<sub>2</sub>-terminus of the secreted form of KGF (beginning with the amino terminal cysteine residue of the mature KGF form, numbered 32 in Fig II-1, and ending at KGF residue 78, arg) is linked to about 140 amino acids of the CO<sub>2</sub>-terminal core of aFGF (beginning at residue 39, arg, and continuing to the C-terminal end of the aFGF coding sequence. This chimeric product has a target cell preference for keratinocytes, like KGF, but lacks susceptibility to heparin, a characteristic which parallels that of aFGF rather than KGF. This novel KGF-like growth factor may have advantages in clinical applications where administration of an epithelial-specific growth factor is desirable in the presence of heparin, a commonly used anticoagulant. Further details of the construction of this chimeric molecule and the properties of the polypeptide are described in Experimental Section II.

[0076] Other DNAs of this invention include the following recombinant DNA molecules comprising a KGF cDNA and any of the following exemplary vector DNAs: a bacteriophage  $\lambda$  cloning vector ( $\lambda$ pCEV9); a DNA sequencing plasmid vector (a pUC variant); a bacterial expression vector (pKK233-2); or a mammalian expression vector (pMMT/neo). Such recombinant DNAs are exemplified by constructs described in detail in the Experimental Sections.

[0077] Most preferred recombinant molecules include the following: molecules comprising the coding sequence for the secreted form of KGF and a bacterial expression vector (e.g., pKK233-2) or a cDNA encoding the entire primary translation product (including the NH<sub>2</sub>-terminal signal peptide) and a mammalian expression vector (exemplified by pMMT) capable of expressing inserted DNAs in mammalian (e.g., NIH/3T3) cells.

[0078] Construction of recombinant DNAs containing KGF DNA and a bacterial expression vector is described in Experimental Section II. In brief, KGF cDNA was expressed to produce polypeptide in *E. coli* by placing its coding sequence under control of the hybrid *trk* promoter in the plasmid expression vector pKK233-2 (II-31).

[0079] Construction of recombinant DNAs comprising KGF DNA and a mammalian vector capable of expressing inserted DNAs in cultured human or animal cells, can be carried out by standard gene expression technology using methods well known in the art for expression of such a relatively simple polypeptide. One specific embodiment of a recombinant DNA of this aspect of the present invention, involving the mammalian vector pMMT, is described further below in this section under recombinant cells of this invention.

[0080] DNAs and sense strand RNAs of this invention can be employed, in conjunction with protein production methods of this invention, to make large quantities of substantially pure KGF or KGF-like proteins. Substantially pure KGF protein thus produced can be employed, using well-known techniques, in diagnostic assays to determine the presence of receptors for this protein in various body fluids and tissue samples.

[0081] Accordingly, this invention also comprises a cell, preferably a bacterial or mammalian cell, comprising a vector with a DNA of the invention, wherein the DNA is capable of being expressed. In a preferred embodiment of this aspect of the invention, the cell transformed by the DNA of the invention produces KGF protein in a fully mitogenic form. Most preferably, these proteins will be of a secreted form (i.e., lacking an apparent signal sequence). These protein factors can be used for functional studies, and can be purified for additional biochemical and functional analyses, such as qualitative and quantitative receptor binding assays.

[0082] Recombinant *E. coli* cells have been constructed in a bacterial expression vector, pKK233-2, for production of KGF, as detailed in Experimental Section II. In summary, several recombinant bacterial clones were tested for protein production by the usual small scale methods. All recombinants tested synthesized a protein that was recognized by antibodies raised against an amino-terminal KGF peptide (see below). One recombinant was grown up in a one liter culture which produced recombinant KGF that efficiently stimulated thymidine incorporation into DNA of BALB/MK keratinocyte cells, but was only marginally active on NIH/3T3 fibroblasts. Half-maximal stimulation of the



BALB/MK cells in the standard keratinocyte bioassay was achieved with a concentration of between 2 to 5 ng/ml, compared to a concentration of 10 to 15 ng/ml for KGF purified from M426 cells.

[0083] One liter of bacterial cells yielded approximately 50 µg of Mono-S purified recombinant KGF. It will be apparent to those skilled in the art of gene expression that this initial yield can be improved substantially without undue experimentation by application of a variety of known recombinant DNA technologies.

[0084] Recombinant mammalian (NIH/3T3 mouse) cells have also been constructed using the entire KGF cDNA coding sequence (including the NH<sub>2</sub>-terminal signal peptide) and the vector pMMT/neo, which carries mouse metallothioneine (MMT) promoter and the selective marker gene for neomycin resistance. The cells are being evaluated for KGF production, particularly for secretion of the mature form (lacking signal peptide) produced by human fibroblasts, using bioassays of the present invention. This same vector and host cell combination has been used successfully to express several other similar recombinant polypeptides, including high levels of Platelet-Derived Growth Factor (PDGF) A and B chains (II-32). Accordingly, it will be recognized by those skilled in the art that high yields of recombinant KGF can

be achieved in this manner, using the aforementioned recombinant DNAs and transformed cells of this invention.

[0085] Ultimately, large-scale production can be used to enable clinical testing in conditions requiring specific stimulation of epithelial cell growth. Materials and methods for preparing pharmaceutical compositions for administration of polypeptides topically (to skin or to the cornea of the eye, for example) or systemically are well known in the art and can be adapted readily for administration at KGF and KGF-like peptides without undue experimentation.

[0086] This invention also comprises novel antibodies made against a peptide encoded by a DNA segment of the invention. This embodiment of the invention is exemplified by several kinds of antibodies which recognize KGF. These have been prepared using standard methodologies well known in the art of experimental immunology, as outlined in Experimental Section II. These antibodies include: monoclonal antibodies raised in mice against intact, purified protein from human fibroblasts; polyclonal antibodies raised in rabbits against synthetic peptides with sequences based on amino acid sequences predicted from the KGF cDNA sequence [exemplified by a peptide with the sequence of KGF residues 32-45, namely, NDMTPEQMATNVR (using standard one-letter code for amino acid sequences; see Fig. II-1)]; polyclonal antibodies raised in rabbits against both naturally secreted KGF from human fibroblasts and recombinant KGF produced in *E. coli* (see above).

[0087] All tested antibodies recognize the recom-

binant as well as the naturally occurring KGF, either in a solid-phase (ELISA) assay and/or in a Western blot. Some exemplary antibodies, which are preferred antibodies of this invention, appear to neutralize mitogenic activity of KGF in the BALB/MK bioassay.

[0088] Fragments of antibodies of this invention, such as Fab or F(ab)' fragments, which retain antigen binding activity and can be prepared by methods well known in the art, also fall within the scope of the present invention. Further, this invention comprises pharmaceutical compositions of the antibodies of this invention, or active fragments thereof, which can be prepared using materials and methods for preparing pharmaceutical compositions for administration of polypeptides that are well known in the art and can be adapted readily for administration of KGF and KGF-like peptides without undue experimentation.

[0089] These antibodies, and active fragments thereof, can be used, for example, for detection of KGF in bioassays or for purification of the protein factors. They may also be used in approaches well known in the art, for isolation of the receptor for KGF, which, as described in Experimental Section II, appears to be distinct from those of all other known growth factors.

[0090] Those preferred antibodies, and fragments and pharmaceutical compositions thereof, which neutralize mitogenic activity of KGF for epithelial cells, as indicated by the BALB/MK assay, for instance, may be used in the treatment of clinical conditions characterized by excessive epithelial cell growth, including dysplasia and neoplasia (e.g., psoriasis, or malignant or benign epithelial tumors).

[0091] This invention further comprises novel bioassay methods for detecting the expression of genes related to DNAs of the invention. In some exemplary embodiments, DNAs of this invention were used as probes to determine steady state levels of related mRNAs. Methods for these bioassays of the invention, using KGF DNAs, and standard Northern blotting techniques, are described in detail in Experimental Section II.

[0092] One skilled in the art will recognize that, without undue experimentation, such methods may be readily applied to analysis of gene expression for KGF-like proteins, either in isolated cells or various tissues. Such bioassays may be useful, for example, for identification of various classes of tumor cells or genetic defects in the epithelial growth processes.

[0093] Without further elaboration, it is believed that one of ordinary skill in the art, using the preceding description, and following the methods of the Experimental Sections below, can utilize the present invention to its fullest extent. The material disclosed in the Experimental Sections, unless otherwise indicated, is disclosed for illustrative purposes and therefore should not be construed as being limitative in any way of the appended claims.

## EXPERIMENTAL SECTION I

### IDENTIFICATION AND CHARACTERIZATION OF A NOVEL GROWTH FACTOR SPECIFIC FOR EPITHELIAL CELLS

[0094] This section describes experimental work leading to identification of a growth factor specific for epithelial cells in conditioned medium of a human embryonic lung fibroblast cell line. The factor, provisionally termed keratinocyte growth factor (KGF) because of its predominant activity on this cell type, was purified to homogeneity by a combination of ultrafiltration, heparin-Sepharose affinity chromatography and hydrophobic chromatography on a  $C_4$  reversed-phase HPLC column, according to methods of this invention. KGF was found to be both acid and heat labile, and consisted of a single polypeptide chain with an apparent molecular weight of approximately 28,000 daltons. Purified KGF was a potent mitogen for epithelial cells, capable of stimulating DNA synthesis in quiescent BALB/MK epidermal keratinocytes by more than 500-fold with activity detectable at 0.1 nM and maximal at 1.0 nM. Lack of mitogenic activity on either fibroblasts or endothelial cells indicated that KGF possessed a target cell specificity distinct from any previously characterized growth factor. Microsequencing revealed an amino-terminal sequence containing no significant homology to any known protein. The release of this novel growth factor by human embryonic fibroblasts indicates that KGF plays a role in mesenchymal stimulation of normal epithelial cell proliferation.

### METHODS AND MATERIALS

[0095] Preparation of Conditioned Media. An early passage of M426 human embryonic fibroblasts (I-8) was plated onto 175 cm<sup>2</sup> T-flasks and grown to confluence over 10-14 days in Dulbecco's modified Eagle's medium (DMEM; GIBCO) supplemented with 10% calf serum (GIBCO). Once confluent, the monolayers were cycled weekly from serum-containing to serum-free medium, the latter consisting of DMEM alone. The cells were washed twice with 5 ml of phosphate buffered saline prior to addition of 20 ml of DMEM. After 72 hrs, culture fluids were collected and replaced with 35 ml of serum-containing medium. The conditioned medium was stored at -70°C until further use.

[0096] Ultrafiltration. Approximately ten liters of conditioned medium were thawed, prefiltered through a 0.50 micron filter (Millipore HAWP 142 50) and concentrated to 200 ml using the Pellicon Cassette system (Millipore XX42 00K 60) and a cassette having a 10 kDa molecular weight cutoff (Millipore PTGC 000 05). After concentration, the sample was subjected to two successive rounds of dilution with one liter of 20 mM Tris-HCl, pH 7.5/0.3M NaCl, each followed by another step of ultrafiltration with the Pellicon system. Activity recovered in the retentate was either immediately applied to

heparin-Sepharose resin or stored at -70°C.

[0097] Heparin-Sepharose Affinity Chromatography (HSAC). The retentate from ultrafiltration was loaded onto heparin-Sepharose resin (Pharmacia) which had been equilibrated in 20 mM Tris-HCl, pH 7.5/0.3 M NaCl. The resin was washed extensively until the optical density had returned to baseline and then subjected to a linear-step gradient of increasing NaCl concentration. After removing aliquots from the fractions for the thymidine incorporation bioassay, selected fractions were concentrated ten- to twenty-fold with a Centricon-10 microconcentrator (Amicon) and stored at -70°C.

[0098] Reversed-Phase HPLC (RP-HPLC). Active fractions (0.6 M NaCl pool) from the HSAC were thawed, pooled and further concentrated with the Centricon-10 to a final volume of  $\leq 200$   $\mu$ l. The sample was loaded onto a Vydac  $C_4$  HPLC column (The separations Group, Hesperia, CA) which had been equilibrated in 0.1% trifluoroacetic acid (TFA, Fluka)/20% acetonitrile (Baker, HPLC grade) and eluted with a linear gradient of increasing acetonitrile. Aliquots for the bioassay were immediately diluted in a 10-fold excess of 50  $\mu$ g/ml BSA (Fraction V, Sigma)/20 mM Tris-HCl, pH 7.5. The remainder of the sample was dried in a Speed-Vac (Savant) in preparation for structural analysis.

[0099] Molecular Sieve HPLC. Approximately 50  $\mu$ l of the twice concentrated heparin-Sepharose fractions were loaded onto a TSK-G3000SW Glas-Pac Column (LKB) which had been equilibrated in 20 mM Tris-HCl, pH 6.8/0.5M NaCl. The sample was eluted in this buffer at a flow rate of 0.4 ml/min. After removing aliquots for the bioassay, the fractions were stored at -70°C.

[0100] NaDodSO<sub>4</sub>-Polyacrylamide Gel Electrophoresis (NaDodSO<sub>4</sub>/PAGE). Polyacrylamide gels were prepared with NaDodSO<sub>4</sub> according to the procedure of Laemmli (I-9). Samples were boiled for 3 min in the presence of 2.5% 2-mercaptoethanol (vol/vol). The gels were fixed and stained with silver (I-10) using the reagents and protocol from BioRad. Molecular weight markers were from Pharmacia.

[0101] DNA Synthesis Stimulation. Ninety-six well microtiter plates (Falcon No. 3596) were precoated with human fibronectin (Collaborative Research) at 1  $\mu$ g/cm<sup>2</sup> prior to seeding with BALB/MK cells. Once confluent, the cells were maintained for 24-72 hr in serum-free medium containing 5  $\mu$ g/ml transferrin (Collaborative Research) and 30 nM Na<sub>2</sub>SeO<sub>3</sub> (Baker). Incorporation of <sup>3</sup>H-thymidine (5  $\mu$ Ci/ml final concentration, NEN) into DNA was measured during a 6 hr period beginning at 16 hrs following addition of samples. The assay was terminated by washing the cells once with ice cold phosphate-buffered saline and twice with 5% trichloroacetic acid. The precipitate was redissolved in 0.25 M NaOH, transferred into liquid scintillation fluid (Biofluor, NEN) and counted.

[0102] Stimulation of DNA synthesis was monitored as described above for BALB/MK cells on a variety of

other cell lines. NIH/3T3 fibroblasts (I-11) were available from the National Institutes of Health, while CCL208 Rhesus monkey bronchial epithelial cells (I-12) were obtained from the American Type Culture Collection. The B5/589 human mammary epithelial cell line, prepared as described in (I-13), was obtained from Martha Stampfer (University of California, Berkeley). The mammary cells were grown in RPMI 1640 supplemented with 10% fetal calf serum and 4 ng/ml EGF. When maintained in serum-free conditions, the basal medium was DMEM. Primary cultures of human saphenous vein endothelial cells were prepared and maintained as described elsewhere (I-14). Epidermal growth factor and insulin were from Collaborative Research. Acidic FGF and bFGF were obtained from California Biotechnology, Inc. Recombinant TGF $\alpha$  was obtained from Genentech, Inc. Media and serum were either from GIBCO, Biofluids, Inc. or the NIH media unit.

**[0103] Proliferation Assay.** Thirty-five mm culture dishes were precoated sequentially with poly-D-lysine (20  $\mu\text{g}/\text{cm}^2$ ) (Sigma) and human fibronectin, and then seeded with approximately  $2.5 \times 10^4$  BALB/MK cells. The basic medium was a 1:1 mixture of Eagle's low  $\text{Ca}^{2+}$  minimal essential medium and Ham's F-12 medium, supplemented with 5  $\mu\text{g}/\text{ml}$  transferrin, 30 nM  $\text{Na}_2\text{SeO}_3$  and 0.2 mM ethanolamine (Sigma). Medium was changed every 2 or 3 days. After 10 days, the cells were fixed in formalin (Fisher Scientific Co.) and stained with Giemsa (Fisher Scientific Co.).

**[0104] Protein microsequencing.** Approximately 4  $\mu\text{g}$  ( $\sim 150$  pmol) of protein from the active fractions of the  $\text{C}_4$  column were redissolved in 50% TFA and loaded onto an Applied Biosystems gas-phase protein sequenator. Twenty rounds of Edman degradation were carried out and identifications of amino acid derivatives were made with an automated on-line HPLC (Model 120A, Applied Biosystems).

## RESULTS

### Growth Factor Detection and Isolation.

**[0105]** Preliminary screening of conditioned media from various cell lines indicated that media from some fibroblast lines contained mitogenic activities detectable on both BALB/MK and NIH/3T3 cells. Whereas boiling destroyed the activity on BALB/MK, mitogenic activity on NIH/3T3 remained intact. Based on the known heat stability of EGF (I-15) and TGF $\alpha$  (I-16), it was reasoned that the BALB/MK mitogenic activity might be due to an agent different from these known epithelial growth factors.

**[0106]** M426, a human embryonic lung fibroblast line, was selected as the most productive source of this activity for purification of the putative growth factor(s). Ultrafiltration with the Pellicon system provided a convenient way of reducing the sample volume to a suitable level for subsequent chromatography. Various combina-

tions of sieving, ion exchange and isoelectric focusing chromatography were tried during the development of a purification scheme, but all resulted in unacceptably low yields. On the other hand, heparin-Sepharose affinity chromatography (HSAC), which has been employed in the purification of other growth factors (I-17--I-22), proved to be useful as an early purification step in the present invention. While estimates of recovered specific activity were uncertain at this stage because of the likely presence of other factors, the apparent yield of activity was 50-70% with a corresponding enrichment of approximately 1000 fold.

**[0107]** As shown in Fig. I-1, greater than 90% of the BALB/MK mitogenic activity eluted from the HSAC column with 0.6M NaCl. This peak of activity was not associated with any activity on NIH/3T3 cells (data not shown). A much smaller peak of BALB/MK mitogenic activity consistently emerged with 0.8 - 1.2M NaCl.

**[0108]** Due to the reproducibility of the HSAC pattern, active fractions could be identified presumptively on the basis of the gradient and optical density profile. Prompt concentration of 10-20 fold with the Centricon-10 was found to be essential for stability, which could be maintained subsequently at  $-70^\circ\text{C}$  for several months.

**[0109]** Final purification was achieved by RP-HPLC with a  $\text{C}_4$  Vydac column, a preparative method suitable for amino acid sequence analysis. While the yield of activity from the  $\text{C}_4$  step was usually only a few percent, this loss could be attributed to the solvents employed. In other experiments, exposure to 0.1% TFA/50% acetonitrile for 1 hr at room temperature reduced the mitogenic activity of the preparation by 98%. Nonetheless, as shown in Fig. I-2, a single peak of BALB/MK stimulatory activity was obtained, coinciding with a distinct peak in the optical density profile. The peak fractions produced a single band upon NaDodSO $_4$ /PAGE and silver staining of the gel (Fig. I-2B), and the relative mitogenic activity of each tested fraction (Fig. I-2C) correlated well with the intensity of the bands across the activity profile.

**[0110]** An alternative purification step to the HPLC technique described above, using sieving chromatography with a TSK G3000SW GlasPac column run in aqueous solution near physiologic pH, resulted in a major peak of activity in the BALB/MK bioassay (Fig. I-3). This preparation was almost as pure as the one obtained from RP-HPLC as judged by silver-stained NaDodSO $_4$ /PAGE (data not shown) but provided a far better recovery of activity (Table I-1). The TSK-purified material was used routinely for biological studies as it had a higher specific activity.

**[0111]** In both types of purified preparations (i.e., purified by HPLC or molecular sieving), the profile of mitogenic activity was associated with a distinct band on NaDodSO $_4$ /PAGE which appeared to be indistinguishable in the two preparations.

**[0112] Physical and Biological Characterization of the Growth Factor.** The purified factor had an estimated

molecular weight of about 28 kDa based on NaDodSO<sub>4</sub>/PAGE under reducing (Fig. 1-2) and non-reducing conditions (data not shown). This value was in good agreement with its elution position on two different sizing columns run in solvents expected to maintain native conformation (TSK-G3000-SW, Fig. 1-3, and superose-12, data not shown). From these data, the mitogen appears to consist of a single polypeptide chain with a molecular weight of 25-30 kDa.

[0113] The heat and acid lability of the mitogenic activity were demonstrated using the BALB/MK mitogenesis bioassay. While activity was unaffected by a 10 min incubation at 50°C, it was reduced by 68% after 10 min at 60°C and was undetectable after 3 min at 100°C. Exposure to 0.5M acetic acid for 60 min at room temperature resulted in a decline in activity to 14% of the control. In comparison, the mitogenic activity of the known growth factor, EGF, was not diminished by any of these treatments.

[0114] The dose response curve for the purified growth factor depicted in Fig. 1-4 illustrates that as little as 0.1 nM led to a detectable stimulation of DNA synthesis. Thus, the activity range was comparable to that of the other growth factors analyzed to date. A linear relationship was observed in the concentration range 0.1 - 1.0 nM with maximal stimulation of 600 fold observed at 1.0 nM. The novel factor consistently induced a higher level of maximal thymidine incorporation than EGF, aFGF, or bFGF in the BALB/MK keratinocytes (Fig. 1-4).

[0115] The distinctive target cell specificity of this factor was demonstrated by comparing its activities on a variety of cell types with those of other growth factors known to possess epithelial cell mitogenic activity. As shown in Table 1-2, the newly isolated factor exhibited a strong mitogenic effect on BALB/MK but also induced demonstrable incorporation of thymidine into DNA of the other epithelial cells tested. In striking contrast, the factor had no detectable mitogenic effects on mouse (or human, data not shown) fibroblasts or human saphenous vein endothelial cells.

[0116] By comparison, none of the other known growth factors appeared to preferentially stimulate keratinocytes. TGF $\alpha$  and EGF showed potent activity on fibroblasts, while the FGFs were mitogenic for endothelial cells as well as fibroblasts (Table 1-2). Because of its specificity of epithelial cells and the sensitivity of keratinocytes in particular, the novel mitogen was provisionally designated as keratinocyte growth factor (KGF).

[0117] To establish that KGF not only would stimulate DNA synthesis but would also support sustained cell growth, the ability of BALB/MK cells to grow in a fully-defined, serum-free medium supplemented with this growth factor was assessed. As shown in Fig. 1-5, KGF served as an excellent substitute for EGF but not insulin (or insulin-like growth factor I) in this chemically defined medium. Thus, KGF appears to act through the major signalling pathway shared by EGF, aFGF and bFGF for proliferation of BALB/MK cells.

[0118] Microsequencing Reveals a Unique N-terminal Amino Acid Sequence of KGF To further characterize the growth factor, approximately 150 pmol of C<sub>4</sub>-purified material were subjected to amino acid sequence analysis. A single sequence was detected with unambiguous assignments made for cycles 2-13, as follows: X-Asn-Asp-Met-Thr-Pro-Glu-Gln-Met-Ala-Thr-Asn-Val. High background noise precluded an assignment for the first position which is, therefore, indicated by an X.

[0119] A computer search using the FASTP program (1-24) revealed that the N-terminal amino acid sequence of KGF showed no significant homology to any protein in the National Biomedical Research Foundation data bank, thus supporting the novelty of this epithelial growth factor.

## DISCUSSION

[0120] The studies described in this Experimental Section identified a human growth factor which has a unique specificity for epithelial cells. By employing ultra-filtration, HSAC and RP-HPLC or TSK sieving chromatography according to the present invention, a quantity sufficient to permit detailed characterization of the physical and biological properties of this molecule was isolated.

[0121] A single silver-stained band corresponding to a molecular weight of about 28,000 daltons was detected in the active fractions from RP-HPLC, and the intensity of the band was proportional to the level of mitogenic activity in these fractions. A band indistinguishable from that obtained by RP-HPLC was seen in the active fractions from TSK chromatography. The purified protein stimulated DNA synthesis in epithelial cells at sub-nanomolar concentrations, but failed to induce any thymidine incorporation in fibroblasts or endothelial cells at comparable or higher concentrations (up to 5 nM). This distinctive target cell specificity combined with the single novel N-terminal amino acid sequence determined from the purified molecule lead to the conclusion that KGF represents a new growth factor.

[0122] In a chemically defined medium the purified factor was able to complement the insulin-like growth factor I/insulin growth requirement of BALB/MK cells and therefore must act through a signal transduction pathway shared with EGF, TGF $\alpha$  and the FGFs. Moreover, the new factor was more potent than any of the known epithelial cell mitogens in stimulating thymidine incorporation in BALB/MK cells. Preliminary evidence indicates that this factor is also capable of supporting proliferation of secondary cultures of human keratinocytes (data not shown).

[0123] Handling and storage of KGF were problematical during its purification. Besides its inherent lability to acid and heat, it was unstable to lyophilization or dialysis. After HSAC, complete loss of activity occurred within 24 hr despite the use of carrier proteins, heparin,

protease inhibitors, siliconized tubes or storage at either 4° or -20°C. Only concentrating the sample at this stage could preserve its activity.

[0124] Furthermore, in order to transfer the dried, purified factor it was necessary to utilize either strong acid or detergent, consistent with an adsorptive tendency or insolubility. Thus, for preservation of activity, the purified factor was maintained in solution at high concentrations at -70°C where it remained stable for several months.

[0125] The ability of KGF to bind heparin may signify a fundamental property of this factor that has a bearing on its function *in vivo*. Growth factors with heparin-binding properties include aFGF (I-20--I-22) bFGF (I-19, I-22) granulocyte/macrophage colony stimulating factor and interleukin 3. (I-25) Each of these is produced by stromal cells (I-25--I-27). Such factors appear to be deposited in the extracellular matrix, or on proteoglycans coating the stromal cell surface (I-25, I-28). It has been postulated that their storage, release and contact with specific target cells are regulated by this interaction (I-25, I-28). While mesenchymal-derived effectors of epithelial cell proliferation have also been described (I-29--I-31), their identities have not been elucidated. Its heparin-binding properties, release by human embryonic fibroblast stromal cells, and epithelial cell tropism provide KGF with all of the properties expected of such a paracrine mediator of normal epithelial cell growth.

[0126] The partial amino acid sequence determined for this new growth factor has enabled molecular cloning of its coding sequence and determination of its structural relationship to known families of growth factors, as described in Experimental Section II, below.

#### REFERENCES FOR EXPERIMENTAL SECTION I

##### [0127]

- I-1. James, R. and Bradshaw, R.A. (1984) *Ann. Rev. Biochem.* **53**, 259-292.
- I-2. Doolittle, R.F., Hunkapiller, M.W., Hood, L.E., Devare, S.G., Robbins, K.C., Aaronson, S.A. and Antoniades, M.N. (1983) *Science* **221**, 275-277.
- I-3. Waterfield, M.D., Scrace, G.J., Whittle, N., Strooband, P., Johnson, A., Wasteton, A., Westermarck, B., Heldin, C.-H., Huang, J.S. and Deuel, T.F. (1983) *Nature* **304**, 35-39.
- I-4. Hunter, T. and Cooper, J.A. (1985) *Annu. Rev. Biochem.* **54**, 897-930.
- I-5. Wright, N. and Allison, M. (1984) *The Biology of Epithelial Cell Populations* (Oxford University Press, New York) Vol. 1, pp. 3-5.
- I-6. Weissman, B.E. and Aaronson, S.A. (1983) *Cell* **32**, 599-606.
- I-7. Falco, J.P., Taylor, W.G., DiFiore, P.P., Weissman, B.E., and Aaronson, S.A. (1988) *Oncogene* **2**, 573-578.
- I-8. Aaronson, S.A. and Todaro, G.J. (1968) *Virology* **36**, 254-261.
- I-9. Laemmli, U.K. (1970) *Nature* **227**, 680-685.
- I-10. Merrill, C.R., Goldman, D., Sedman, S.A. and Ebert, M.H. (1981) *Science* **211**, 1437-1438.
- I-11. Jainchill, J.L., Aaronson, S.A. and Todaro, G.J. (1969) *J. Virol.* **4**, 549-553.
- I-12. Caputo, J.L., Hay, R.J. and Williams, C.D. (1979) *In Vitro* **15**, 222-223.
- I-13. Stampfer, M.R. and Bartley, J.C. (1985) *Proc. Natl. Acad. Sci. USA* **82**, 2394-2398.
- I-14. Sharefkin, J.B., Fairchild, K.D., Albus, R.A., Cruess, D.F. and Rich, N.M. (1986) *J. Surgical Res.* **41**, 463-472.
- I-15. Cohen, S. (1962) *J. Biol. Chem.* **237**, 1555-1562.
- I-16. DeLarco, J.E. and Todaro, G.J. (1978) *Proc. Natl. Acad. Sci. USA* **75**, 4001-4005.
- I-17. Raines, E.W. and Ross, R. (1982) *J. Biol. Chem.* **257**, 5154-5160.
- I-18. Shing, Y., Folkman, J., Sullivan, R., Butterfield, C., Murray, J. and Klagsburn, M. (1984) *Science* **223**, 1296-1299.
- I-19. Gospodarowicz, D., Cheng, J., Lui, G.-M., Baird, A. and Bohlen, P. (1984) *Proc. Natl. Acad. Sci. USA* **81**, 6963-6967.
- I-20. Maciag, T., Mehlman, T., Friesel, R. and Schreiber, A.B. (1984) *Science* **225**, 932-935.
- I-21. Conn, G. and Hatcher, V.B. (1984) *Biochem. Biophys. Res. Comm.* **124**, 262-268.
- I-22. Lobb, R.R. and Fett, J.W. (1984) *Biochemistry* **23**, 6295-6299.
- I-23. Bradford, M. (1976) *Anal. Biochem.* **72**, 248-254.
- I-24. Lipman, D.J. and Pearson, R.W. (1985) *Science* **227**, 1435-1441.
- I-25. Roberts, R., Gallagher, J., Spooncer, E., Allen, T.D., Bloomfield, F. and Dexter, T.M. (1988) *Nature* **332**, 376-378.
- I-26. Libermann, T.A., Friesel, R., Jaye, M., Lyall, R.M., Westermarck, B., Drohen, W., Schmidt, A., Maciag, T. and Schlessinger, J. (1987) *EMBO J.* **6**, 1627-1632.
- I-27. Shipley, G.D., Sternfeld, M.D., Coffey, R.J. and Pittelkow, M.R. (1988) *J. Cell Biochem. Supp* **12A**, 125, abstr. C420.
- I-28. Vlodavsky, I., Folkman, J., Sullivan, R., Fridman, R., Ishai-Michaeli, R., Sasse, J. and Klagsburn, M. (1987) *Proc. Natl. Acad. Sci. USA* **84**, 2292-2296.
- I-29. Gilchrist, B.A., Karassik, R.L., Wilkins, L.M., Vrabel, M.A. and Maciag, T. (1983) *J. Cell Physiol.* **117**, 2325-240.
- I-30. Chan, K.Y. and Haschke, R.H. (1983) *Exp. Eye Res.* **36**, 231-246.
- I-31. Stiles, A.D., Smith, B.T. and Post, M. (1986) *Exp. Lung Res.* **11**, 165-177.

## EXPERIMENTAL SECTION II

### cDNA SEQUENCE OF A NOVEL EPITHELIAL CELL SPECIFIC GROWTH FACTOR DEFINES A NEW MEMBER OF THE FGF FAMILY

[0128] Work in the previous Experimental Section I identified and purified a novel heparin-binding growth factor, designated keratinocyte growth factor (KGF), which is particularly active on keratinocytes and appears to be specific for epithelial cells. This second Experimental Section describes the isolation and characterization of cDNA clones encoding KGF, using synthetic oligonucleotides, based upon the experimentally determined NH<sub>2</sub>-terminal amino acid sequence, as hybridization probes. Nucleotide sequence analysis identified a 582-bp open reading frame which would code for a 194-amino acid polypeptide that is between 41% and 33% identical to the heparin-binding acidic and basic fibroblast growth factors (FGFs), and the related products of the *hst* and *int-2* oncogenes. The KGF gene RNA transcript is expressed in normal fibroblasts of both embryonic and adult origin, but not in epithelial, endothelial or glial cells. Thus, KGF appears to be normally expressed by the mesenchyme, indicating a role in the regulation of epithelial cell proliferation.

## MATERIALS AND METHODS

[0129] Isolation of cDNA clones. The purification and N-terminal sequencing of KGF has been previously described (see Experimental Section I, above and II-3). Pools (50 pmole) of deoxyoligonucleotides described under Results were 5' end-labelled using 83 pmole of  $\gamma$ -<sup>32</sup>P-ATP (3000 Ci/mmol, Amersham) and 10 units of T4 polynucleotide kinase. The recombinant phage carrying cDNA clones were replica plated onto nitrocellulose filters and hybridized with <sup>32</sup>P-labelled deoxyoligonucleotides in 20% formamide, 10% dextran sulphate, 10 mM Tris-HCl (pH 7.5), 8 x SSC, 5x Denhardt's and 50  $\mu$ g/ml denatured salmon sperm DNA, overnight at 42°C. Filters were washed in 0.5 x SSC, 0.1% SDS at 50°C and exposed to Kodak X-omat AR film.

[0130] DNA sequencing. The nucleotide sequence of the KGF cDNA was determined by the dideoxy chain termination method (II-26), of overlapping restriction fragments, subcloned into pUC vectors (II-27)

[0131] Construction of a bacterial expression vector for KGF cDNA. KGF cDNA encoding the mature, secreted form of the polypeptide was placed under control of the hybrid *trk* promoter in the plasmid expression vector pKK233-2 (II-31), as follows. To accomplish this, a specific length of KGF cDNA that contained the information to code for the mature KGF molecule (i.e., without its signal peptide) was amplified using the polymerase chain reaction (PCR) technique (II-32). The fragment was directionally inserted between two sites in

the vector, namely the *Nco*I site, made blunt ended by S1 nuclease digestion, and the *Hind*III site, using standard recombinant DNA methodology. The ends of the KGF cDNA produced by the PCR method were as follows: the 5' end was blunt and began with an ATG codon, followed by the codon TGC for cyst residue, number 33, which is the amino terminal residue of the mature form of KGF (see Fig. II-1), and then the entire KGF coding sequence. The stop codon, TAA, and the four bases immediately following, TTGC, were also included on the 3' end of the cDNA. The primer used in the PCR method to direct DNA synthesis to the desired position on the 3' end of the cDNA included a *Hind*III site for insertion of the amplified cDNA into the vector DNA.

[0132] Production of antibodies against KGF and KGF-related peptides. Monoclonal antibodies were raised in mice against intact, purified protein from human fibroblasts using 5 or more subcutaneous injections. Test bleeds were screened with a solid-phase (ELISA) assay using highly purified KGF from human epithelial cells as antigen. Hybridomas were prepared by routine methods and supernatants were screened with the ELISA assay to detect KGF-reactive antibodies. Positive clones were serially subcloned by the usual methods, and selected subclones were grown as ascites tumors in mice for production of large amounts of antibodies. Antibodies were purified from ascites fluids employing standard techniques (e.g., hydroxyapatite or immunoaffinity resins).

[0133] Polyclonal antibodies against a synthetic peptide were raised in rabbits by standard methods, as follows. The peptides were made by solid phase technology and coupled to thyroglobulin by reaction with glutaraldehyde. Serial subcutaneous injections were made and test bleed were screened by ELISA as well as other techniques, including Western blot analysis and mitogenesis bioassay. IgG immunoglobulins were isolated by affinity chromatography using immobilized protein G.

[0134] Polyclonal antibodies were raised in rabbits against both naturally secreted KGF from human fibroblasts and recombinant KGF produced in *E. coli* (see next section), using the following protocol:

- i) Initial injection and first boost were administered in the inguinal lymph nodes;
- ii) subsequent boosts were made intramuscularly.

Screening of test bleeds included ELISA as well as Western blot analysis and mitogenesis bioassay, and IgG was purified as for antibodies against synthetic peptides, above.

## RESULTS

[0135] Isolation of cDNA clones encoding the novel growth factor. To search for cDNA clones corresponding



to the KGF coding sequence, two pools of oligonucleotides with lengths of 26 bases were generated based upon a nine-amino acid sequence, Asn-Asp-Met-Thr-Pro-Glu-Gln-Met-Ala, as determined by microsequencing of purified KGF (see Experimental Section I, above and reference II-3). One oligonucleotide pool contained a mixture of all 256 possible coding sequences for the nine amino acids, while the other contained inosine residues at the degenerate third position of the codons for Thr and Pro.

[0136] This latter design reduced the number of possible coding sequences in the pool to 16. Inosine in a tRNA anticodon can form hydrogen bonds with A, C or U (II-4), and oligonucleotides that contain deoxyinosine have been shown to hybridize efficiently with the corresponding cDNA (II-5).

[0137] A cDNA library was constructed in a cDNA cloning vector, pCEV9 (II-6) using polyadenylated RNA extracted from the human embryonic lung fibroblast cell line M426 (II-7), the initial source of the growth factor. Screening of the library ( $9 \times 10^5$  plaques) with the  $^{32}\text{P}$ -labelled 26-mer oligonucleotides identified 88 plaques which hybridized to both pools of oligonucleotide probes.

[0138] Characterization and sequencing of selected cDNA clones. Of 10 plaque-purified clones that were analyzed, one, designated clone 49, had a cDNA insert of 3.5 kb, while the rest had inserts ranging from 1.8 kb to 2.1 kb.

[0139] Analysis of the smaller clones revealed several common restriction sites. Sequencing of a representative smaller clone, designated clone 32, along with clone 49, demonstrated that they were overlapping cDNAs (Fig II-1A). Whereas clone 49 was primed from the poly(A) tail of the message, clone 32 arose during the construction of the library by hybridization of the oligo (dT) primer to an A-rich sequence in the 3' non-coding region of the KGF mRNA.

[0140] Description of the sequence encoding the KGF polypeptide. Alignment of the two cDNAs (clones 32 and 49) established a continuous sequence of 3.85 kb containing the complete KGF coding sequence (Fig. II-1B). An ATG likely to be an initiation codon was located at nucleotide position 446, establishing a 582-base pair open reading frame that ended at a TAA termination codon at position 1030. This open reading frame would encode a 194-amino acid polypeptide with a calculated molecular weight of 22,512 daltons.

[0141] The sequence flanking the ATG codon did not conform to the proposed GCC(G/A)CCATGG consensus for optimal initiation by eukaryotic ribosomes (II-8), however, there was an A three nucleotides upstream of the ATG codon. An A at this position is the most highly conserved nucleotide in the consensus. This ATG codon was preceded 85 nucleotides upstream by a TGA stop codon in the same reading frame.

[0142] A 19-amino acid sequence that was homologous to the experimentally determined  $\text{NH}_2$ -terminus of

purified KGF began 32 amino acids downstream of the proposed initiation codon. There was complete agreement between the predicted and experimentally determined amino acid sequences, where unambiguous assignments could be made.

[0143] To search for homology between KGF and any known protein, a computer search of the National Biomedical Research Foundation data base using the FASTP program of Lipman and Pearson was conducted (II-9). By this approach, a striking degree of relatedness between the predicted primary structure of KGF and those of acidic and basic FGF, as well as the related *hst* and *int-2*-encoded proteins was revealed.

[0144] Expression of mRNA transcripts of the KGF gene in human cells. In preliminary attempts to examine expression of KGF mRNA in human cells, a probe spanning the majority of the KGF coding sequence (Probe A, Figure II-1A) detected a single 2.4 kb transcript by Northern blot analysis of total M426 RNA (Figure II-1C). This was considerably shorter than the length of the composite cDNA sequence, 3.85 kb.

[0145] However, on screening poly(A)-selected M426 RNA, an additional transcript of approximately 5 kb was detected. Furthermore, a probe derived from the untranslated region of clone 49, 3' to the end of clone 32 (Probe B, Figure II-1A), hybridized only to the larger message (Figure II-1C). Thus, it appears that the KGF gene is transcribed as to alternate RNAs. Two other members of the FGF gene family, bFGF (II-29) and *int-2* (II-30), also express multiple RNAs, the significance of which remains to be determined.

[0146] To investigate the normal functional role of KGF, the expression of its transcript in a variety of human cell lines and tissues was examined. As shown in Figure II-3, the predominant 2.4 kb KGF transcript was detected in each of several stromal fibroblast lines derived from epithelial tissues of embryonic, neonatal and adult sources, but not from epithelial cell lines of normal origin. The transcript was also detected in RNA extracted from normal adult kidneys and organs of the gastrointestinal tract, but not from lung or brain. The striking specificity of KGF RNA expression in stromal cells from epithelial tissues indicated that this factor plays a normal role in mesenchymal stimulation of epithelial cell growth.

[0147] For comparison, the mRNAs of other growth factors with known activity on epithelial cells were also analyzed in the same tissues as listed above. Among the epithelial and stromal cell lines analyzed, there was no consistent pattern of expression of aFGF or bFGF transcripts (Fig. II-3). The EGF transcript was not expressed in any of the same cell lines, and was only observed in kidney, among the various tissues. Finally, the  $\text{TGF}\alpha$  message was not detected in any of the stromal fibroblast lines and was expressed at varying levels in each of the epithelial cell lines. It was also detected at low levels in kidney among the tissues examined (Fig. II-3).

[0148] Inhibition of KGF mitogenic activity by heparin. Heparin has been shown to substantially increase the mitogenic activity of aFGF for a variety of target cells in culture, and to stabilize it from heat inactivation (II-21, II-22). Despite binding tightly to bFGF, heparin had minimal effects on its mitogenic activity (II-22). In view of the relatedness of KGF to the FGFs, the effect of heparin on KGF mitogenic activity was examined. As shown in Table II-1, thymidine incorporation by BALB/MK cells in response to KGF was inhibited 16 fold when heparin was included in the culture medium. In contrast, the activities of both aFGF and bFGF were increased by the same treatment.

[0149] Production of anti-KGF antibodies. Several kinds of antibodies which recognize KGF or KGF-like polypeptides have been prepared using standard methodologies well known in the art of experimental immunology and summarized in the Methods section, above. These include: monoclonal antibodies raised in mice against intact, purified protein from human fibroblasts; polyclonal antibodies raised in rabbits against synthetic peptides with sequences based on amino acid sequences predicted from the KGF cDNA sequence; polyclonal antibodies raised in rabbits against both naturally secreted KGF from human fibroblasts and recombinant KGF produced in *E.coli* (see next section).

[0150] Monoclonal antibodies from three different hybridomas have been purified. All three recognize the recombinant as well as the naturally occurring KGF in a solid-phase (ELISA) assay. None cross-reacts with KGF under denaturing conditions (in a Western blot), and none neutralizes mitogenic activity of KGF in the BALB/MK bioassay.

[0151] Polyclonal antibodies were generated with a synthetic peptide with the amino acid sequence NDMT-PEQMATNVR, corresponding to residues numbered 32 through 44 in KGF (see Fig. II-1), plus an R (arg) residue instead of the actual asp residue encoded by the cDNA at position 45. The asp residue is probably glycosylated in the natural KGF polypeptide and, therefore, appeared to be an arg in the amino acid sequencing data obtained directly from that polypeptide (see Discussion, below). Polyclonal antibodies generated with this synthetic peptide recognize both naturally occurring and recombinant KGF in ELISA and Western blot analyses at a level of sensitivity of at least as low as 10 ng protein. These antibodies, however, do not neutralize mitogenic activity of KGF in the BALB/MK bioassay.

[0152] Polyclonal antisera against intact natural KGF protein recognizes KGF in both ELISA and Western blot assays. Such antibodies also appear to inhibit mitogenic activity of KGF in the BALB/MK bioassay.

[0153] Expression of KGF cDNA in *E.coli*. KGF cDNA was expressed to produce polypeptide in *E. coli* by placing its coding sequence under control of the hybrid *trk* promoter (comprising elements of *trp* and *lac* promoters), in the plasmid pKK233-2 (II-31). To accomplish this, a specific length of KGF cDNA that contained

the information to code for the mature KGF molecule (i.e., without its signal peptide) was amplified using the polymerase chain reaction technique (II-32). The fragment was directionally inserted between two sites in the vector, namely the *NcoI* site, made blunt ended by *S1* nuclease digestion, and the *HindIII* site, using standard recombinant DNA methodology. Selected recombinants were sequenced at their cDNA 5' ends to ensure correct alignment of the ATG initiation codon with the regulatory elements of the *trk* promoter.

[0154] Several recombinants were tested for protein production by the usual small scale methods. In brief, the clones were grown to mid-exponential phase (OD<sub>595</sub> ~0.5), treated with 1 mM isopropyl  $\beta$ -D-thiogalactopyranoside (IPTG) for 90 minutes, and cell extracts were run on SDS-polyacrylamide gels for Western blot analysis. All recombinants tested synthesized a protein that was recognized by antibodies raised against an amino-terminal KGF peptide. One recombinant was selected which showed the greatest induction from IPTG, for further protein analyses.

[0155] One liter of bacteria was grown up in NZY broth containing 50  $\mu$ g/ml ampicillin and 12.5  $\mu$ g/ml tetracycline, to OD<sub>595</sub> ~0.5, and treated for 90 min. with IPTG. The cells were collected by centrifugation, resuspended in 50 mM sodium phosphate (pH 7.3), 0.2 M NaCl, and lysed by sonication. Cell debris was removed by centrifugation, and lysate applied directly to a heparin-Sepharose affinity column.

[0156] As determined by Western blot analysis and mitogenic activity in keratinocytes, recombinant KGF was eluted in 0.5-0.6 M NaCl. Subsequent purification of the HSAC material with a Mono-S (FPLC) column (Pharmacia) yielded a preparation of KGF estimated to be  $\geq 90\%$  pure, as judged by electrophoretic analysis using SDS-polyacrylamide gels and silver-staining.

[0157] Recombinant KGF efficiently stimulated thymidine incorporation into BALB/MK keratinocyte cells, but was only marginally active on NIH/3T3 fibroblasts. Half-maximal stimulation of the BALB/MK cells in the standard keratinocyte bioassay was achieved with a concentration of between 2 to 5 ng/ml, compared to a concentration of 10 to 15 ng/ml for KGF purified from M426 cells. One liter of bacterial cells yielded approximately 50  $\mu$ g of Mono-S purified recombinant KGF.

[0158] Construction of a chimera containing KGF and aFGF sequences. The studies above indicated that KGF possessed two distinctive characteristics which might be encoded by distinct portions or domains of the polypeptide sequence, as is well known to occur in coding sequences of other multifunctional polypeptides. To test this possibility, a chimeric DNA segment encoding the NH<sub>2</sub>-terminal sequence of KGF grafted onto the C-terminal core of aFGF was constructed, as follows. A *Sau3A*I restriction enzyme site (GATC) in the 5' end of the KGF cDNA, within codons for residues 78 and 79 (arg and ile, respectively; see Fig. II-1) was cut and joined to an homologous site in the aFGF cDNA within

codons for amino acids 39 (arg) and 40. The 3' and 5' ends of this chimeric DNA were joined to the vector DNA of the plasmid pKK233-2 by the same method used for insertion of the KGF cDNA encoding the secreted form of polypeptide (see Methods, above).

[0159] When recombinant *E. coli* cells were constructed using the vector carrying the chimera, and expressions tests were conducted as described for mature KGF, above, a novel product with properties of both KGF and aFGF was produced. The peptide was enriched by heparin-Sepharose chromatography and found to have a target cell preference for keratinocytes, like KGF, with minimal activity on fibroblasts (NIH/3T3). The mitogenic activity of this chimeric polypeptide lacks, however, susceptibility to inhibition by heparin, a characteristic which parallels that of aFGF rather than KGF. In fact, the mitogenic activity on keratinocytes is actually enhanced by heparin, as is the case for aFGF. Thus the peptide domains responsible for cell target specificity and heparin sensitivity are clearly distinct and readily separable in KGF, according to the practice of the present invention.

#### DISCUSSION

[0160] The experiments described in this section illustrate the practice of several principal embodiments of the present invention. These include isolation of cDNAs encoding KGF, expression of such cDNAs in recombinant cells; production of various antibodies reactive with KGF, and construction and expression of a chimeric cDNA encoding a novel growth factor with amino acid sequences and related functionalities of both KGF and aFGF. The following points related to these embodiments may also be noted to enhance the understanding of the present invention.

[0161] The sequence predicted from the KGF cDNA agreed with the amino acid sequence determined from the purified KGF form secreted by human fibroblasts. Moreover, the sequence offered potential explanations for positions where definitive amino acid assignments could not be made by direct amino acid sequencing. Residues 32 and 46 are predicted from the cDNA sequence to be cysteines, and hydrolyzed derivatives of unmodified cysteine residues are not detectable following Edman degradation. The predicted KGF amino acid sequence also contained one potential N-linked glycosylation site (Asn-X-Ser/Thr) from residues 45 through 47. If Asn 45 were glycosylated, it would not be detected by the amino acid sequencing methods employed here. In fact, KGF migrates as a broad band on NaDodSO<sub>4</sub>/PAGE at a higher molecular weight than predicted for the purified protein. This is may be accounted for by glycosylation.

[0162] The FGFs are heparin-binding mitogens with broad target cell specificities (II-10). The *hst* gene was identified as a transforming gene from a human stomach tumor (II-11), adjacent normal stomach tissue

(II-12), and from Kaposi's sarcoma (II-13), by standard NIH/3T3 transfection assays. The product of the *int-2* gene is expressed normally during mouse embryogenesis (II-14) and aberrantly after proviral integration of mouse mammary tumor virus (II-15).

[0163] KGF is the sixth member of the fibroblast growth factor family to be identified (II-28). While the name FGF-6 does not seem suitable because KGF is devoid of activity on fibroblasts, this nomenclature may also be used for this growth factor, to denote its structural relationship to the FGF family. As all previously characterized growth factors either exclude epithelial cells as targets or include them among a number of sensitive target cells, the highly specific nature of KGF mitogenic activity for epithelial cells, and the sensitivity of keratinocytes in particular, make it unique.

[0164] In studies to date, expression of the KGF transcript appears to be specific for stromal cells derived from epithelial tissues, suggesting its function in normal epithelial cell proliferation. The availability of the KGF cDNA clone will make it possible to determine whether abnormal expression of this growth factor can be implicated in clinical conditions characterized by epithelial cell dysplasia and/or neoplasia. Moreover, the ability to produce large quantities of this novel growth factor by recombinant techniques should allow testing of its clinical applicability in situations where specific growth of epithelial cells is of particular importance.

[0165] Alignment of the KGF sequence with the five other proteins of the FGF family revealed two major regions of homology, spanning amino acids 65-156 and 162-189 in the predicted KGF sequence, which were separated by a short, nonhomologous series of amino acids with varying lengths in different members of the family (Fig. II-2). In the case of *int-2*, the length of this sequence was 17 residues, while in *hst*, the two homologous regions were contiguous. In KGF the intervening sequence consisted of five amino acids.

[0166] In the aligned regions, the KGF amino acid sequence was about 44% identical to *int-2* (mouse), 39% identical to bFGF (human), 37% identical to aFGF (human) and 33% identical to *hst* (human). In this same region, all six proteins were identical at 19% of the residues, and allowing for conservative substitutions, they showed 28% homology.

[0167] As shown in Fig. II-2, the amino termini of these related proteins are nonhomologous and of variable length. The primary KGF and *hst* translation products contain hydrophobic N-terminal regions which likely serve as signal sequences (II-16). The fact that this N-terminal domain is not present in the mature KGF molecule (Fig. II-1B) further supports this conclusion. In contrast, the FGFs are synthesized apparently without signal peptides (II-10). The *int-2* protein contains an atypically short region of N-terminal hydrophobic residues (II-17), but it is not known if the protein is secreted. Moreover, the *int-2* protein contains a long C-terminal extension compared to the other family members.

[0168] Purified KGF contains five cysteine residues, two of which are conserved throughout the family of FGF related proteins (Fig. II-2). Also of note are the five pairs of basic residues throughout the KGF sequence. This same pattern has been observed in other FGF family members and may be involved in their interaction with heparin (II-18). Dibasic sites are also common targets for proteolytic processing and such processing might account for the microheterogeneity observed in some KGF preparations (unpublished data).

[0169] The KGF cDNA sequence was AT rich throughout its length, but particularly so in the 3' untranslated region where the AT content was 70% as compared to 60% in the putative coding sequence and 63% in the 5' untranslated region. The 3' untranslated region contained a large number of ATTTA sequences, which have been proposed to be involved in the selected degradation of transiently expressed, unstable RNAs (II-19). There was no classical AATAAA polyadenylation signal but two variant sequences, AATTAA and AATACA (II-20), were detected 24 and 19 nucleotides, respectively, upstream of the poly(A) sequence at the 3' end of the cDNA.

[0170] It has been suggested that the heparin effect on acidic FGF is either due to stabilization of the active conformation of the growth factor or to formation of a tertiary complex with acidic FGF and its receptor (II-21, II-22). If so, heparin may stabilize a conformation of KGF that is not as active as the free molecule, or form a tight complex that is unable to efficiently interact with its receptor.

[0171] While its ability to bind heparin reflects the structural similarities of KGF with the FGF's, the differences in target cell specificities between these related mitogens is remarkable. The FGF's induce division of most nonterminally differentiated cells of both embryonic mesodermal and neuroectodermal origin. In addition to fibroblasts and vascular endothelial tissues, mesodermally derived targets in culture include myoblasts, chondrocytes and osteoblasts (II-23). FGF's are also mitogenic for glial astrocytes and neuroblasts (II-24). The product of the oncogene isolated from Kaposi's sarcoma, which is identical to *hst*, also stimulates proliferation of NIH/3T3 and capillary endothelial cells (II-25). To date, KGF induced mitogenesis has only been observed in epithelial cells, and the absence of any detectable activity in fibroblasts or endothelial cells has also been demonstrated (see Experimental Section I, above and II-3). It seems likely, therefore, that KGF acts through a different cell surface receptor than the FGFs.

[0172] There is no significant N-terminal homology between KGF and other FGF-related proteins. Thus, the construction of chimeric molecules between KGF and a prototype FGF was undertaken to determine whether the KGF N-terminal domain is sufficient to account for its unique target cell specificity. The results on the first such recombinant polypeptide sequence

indicate that the N-terminal domain of KGF essentially encodes the cell preference for keratinocytes, while the susceptibility of KGF to heparin is encoded somewhere in the C-terminal core region which was replaced by sequences of aFGF. This novel KGF-like growth factor may have advantages in clinical applications where administration of an epithelial-specific growth factor is desirable in the presence of heparin, a commonly used anticoagulant. Additional studies on chimeras should also provide insights into which specific domains in the C-terminal core contribute the different effects of heparin on their biologic activities.

## REFERENCES FOR EXPERIMENTAL II

[0173]

- II-1. James, R. and Bradshaw, R. A. (1984) *Ann. Rev. Biochem.* **53**, 259-292.
- II-2. Sporn, M. B. and Todaro, G. J. (1980) *N. Eng. J. Med.* **303**, 878-880.
- II-3. Rubin, J. S., Osada, H., Finch, P. W., Taylor, W. G., Rudikoff, S. and Aaronson, S. A. (1989) *Proc. Natl. Acad. Sci. USA* (in press).
- II-4. Crick, F. H. C. (1966) *J. Mol. Biol.* **19**, 548-555.
- II-5. Ohtsuka, E., Matsuki, S., Ikehara, M., Takashi, Y. and Matsubara, K. (1985) *J. Biol. Chem.* **260**, 2605-2608.
- II-6. Miki, T., Matsui, T., Heidaran, M. and Aaronson, S. A. (1989) *Proc. Natl. Acad. Sci.* (in press).
- II-7. Aaronson, S. A. and Todaro, G. J. (1968) *Virology* **36**, 254-261.
- II-8. Kozak, M. (1987) *Nucl. Acids Res.* **13**, 8125-8148.
- II-9. Lipman, D. J. and Pearson, R. W. (1985) *Science* **227**, 1435-1441.
- II-10. Thomas, K. (1987) *FASEB J.* **1**, 434-440.
- II-11. Taira, M., Yoshida, T., Miyagawa, K., Sakamoto, H., Terada, M. and Sugimara, T. (1987) *Proc. Natl. Acad. Sci. USA* **84**, 2980-2984.
- II-12. Yoshida, T., Miyagawa, K., Odagiri, H., Sakamoto, H., Little, P. F. R., Terada, M. and Sugimara, T. (1987) *Proc. Natl. Acad. Sci. USA* **84**, 7305-7309.
- II-13. Delli-Bovi, P. and Basillico, C. (1987) *Proc. Natl. Acad. Sci. USA* **84**, 5660-5664.
- II-14. Jakobovits, A., Shackelford, G. M., Varmus, H. E. and Martin, G. R. (1986) *Proc. Natl. Acad. Sci. USA* **83**, 7806-7810.
- II-15. Peters, G., Brookes, S. and Dickson, S. (1983) *Cell* **33**, 364-377.
- II-16. von Heijne, G. (1986) *Nucl. Acids Res.* **14**, 4683-4690.
- II-17. Moore, R. Casey, G., Brookes, S., Dixon, M., Peters, G. and Dickson, C. (1986) *EMBO J.*

- 5, 919-924.
- II-18. Schwarzbauer, J.E., Tamkun, J.M., Lemischka, I. R. and Hynes, R. O. (1983) *Cell* 35, 421-431.
- II-19. Shaw, G. and Kamen, R. (1986) *Cell* 46, 659-667.
- II-20. Birnstiel, M. L., Busslinger, M. and Strub, K. (1985) *Cell* 41, 349-359.
- II-21. Schrieber, A. B., Kenny, J., Kowalski, W., Friesel, J., Mehlman, T. and Maciag, T. (1985) *Proc Natl. Acad. Sci. USA* 82, 6138-6142.
- II-22. Gospodarowicz, O. and Cheng, J. (1986) *J. Cell Physiol.* 128, 475-485.
- II-23. Thomas, K. A. and Gimenez-Gallego, G. (1986) *Trends Biochem. Soc.* 11, 81-84.
- II-24. Gensburger, C., Labourdette, G. and Sensebrenner, M. (1987) *FEBS Lett.* 217, 1-5.
- II-25. Delli-Bovi, P., Curatola, A. M., Kern, F. G., Greco, A., Ittman, M. and Basilico, C. (1987) *Cell* 50, 729-737.
- II-26. Sanger, F., Nicklen, S. and Coulson, A. R. (1977) *Proc. Natl. Acad. Sci. USA* 74, 5463-5467.
- II-27. Yanisch-Perron, C., Vieira, J. and Messing, J. (1985) *Gene* 33, 103-119.
- II-28. Zhan, X., Bates, B., Hu, X. and Goldfarb, M. (1988) *Mol. Cell. Biol.* 8, 3487-3495.
- II-29. Abrahams J. A., Mergia, A., Whang, J.L., Tumolo, A., Friedman, J., Hjerrild, K. A., Gospodarowicz, D. and Fiddes, J. C. (1986) *Science* 233, 545-548.
- II-30. Mansour, S. L. and Martin, G. R. (1988) *EMBO J.* 1, 2035-2041.
- II-31. Amman, E. and Brosius, J. (1985) *Gene* 40, 183.
- II-32. Sakai, R. K., Scharf, S., Faloona, F., Mullis, K.B., Norn, G.T., Erlich, H.A. and Arnheim, N. (1985) *Science* 230, 1350-1354.
- II-33. Beckman, P.M., Betsholtz, C. Heldin, C-H., Westermark, B. DiMarco, E., DiFiore, P.P., Robbins, K.C. and Aaronson, S. A. (1988) *Science* 241, 1346-1349.

[0174] For purposes of completing the background description and present disclosure, each of the published articles, patents and patent applications heretofore identified in this specification are hereby incorporated by reference into the specification.

[0175] The foregoing invention has been described in some detail for purposes of clarity and understanding. It will also be obvious that various combinations in form and detail can be made without departing from the scope of the invention.

## Claims

Claims for the following Contracting States : AT, BE, CH, LI, DE, DK, FR, GB, IT, LU, NL, SE

1. An isolated glycosylated or unglycosylated keratinocyte growth factor (KGF) protein comprising: (a) the following amino acid sequence, (b) a portion of the following amino acid sequence without the N-terminal 31 amino acids, or (c) an amino acid sequence that differs by the addition, deletion, or substitution of one or more amino acids from the following amino acid sequence:

```
MHKWILTWILPTLLYRSCFHIICL
VGTISLACNDMTPEQMATNVNCS
SPERHTRS DYMEGGDIRVRLF
CRTQWYLRIKRGKVKGTQEMK
N
NYNIMEIRTVAVGIVAIGVSEF
YLAMNKEGKLYAKKECNEDCNFK
ELILENHNTYASAKWTHNGGEM
FVALNQKGIPVRGKKTKEQKTA
HFLPMAIT
```

wherein said protein is capable of stimulating DNA synthesis in quiescent BALB/MK epidermal keratinocytes by more than 500-fold while lacking mitogenic activity on fibroblasts and endothelial cells.

2. The KGF protein of claim 1, wherein 5 nM of said protein exhibits less than one-fold stimulation over background in NIH/3T3 fibroblasts.
3. The KGF protein of any of claims 1 to 2 which has a specific activity of at least about  $3.4 \times 10^4$  units per milligram of protein, where one unit of activity is defined as that amount which causes half of the maximal possible stimulation of DNA synthesis in BALB/MK keratinocyte cells.
4. The KGF protein of any of claims 1 to 3 which is glycosylated.
5. The KGF protein of any of claims 1 to 3 which is not glycosylated.
6. The KGF protein of any of claims 1 to 5 comprising the amino acid sequence:

```
CNDMTPEQMATNVNCS
SPERHTRS DYMEGGDIRVRLF
CRTQWYLRIKRGKVKGTQEMK
N
NYNIMEIRTVAVGIVAIGVSEF
YLAMNKEGKLYAKKECNEDCNFK
ELILENHNTYASAKWTHNGGEM
```

FVALNQKGIPVRGKKTKEQKTA  
HFLPMAIT.

7. The KGF protein of any of claims 1 to 5, comprising an amino acid sequence differing by the addition, deletion, or substitution of one or more amino acids from the following amino acid sequence:

CNDMTPEQMATNVNCS  
SPERHTRSVDYMEGGDIRVRRLF<sup>10</sup>  
CRTQWYLRIKRGKVKGTQEMK  
N  
NYNIMEIRTVAVGIVAIGVSEF  
YLAMNKEGKLYAKKECNEDCNFK  
ELILENHYNITYASAKWTHNGGEM<sup>15</sup>  
FVALNQKGIPVRGKKTKEQKTA  
HFLPMAIT

8. The KGF protein of any of claims 1 to 5, comprising an amino acid sequence differing by the addition, deletion or substitution of one or more amino acids from the following amino acid sequence:

MHKWILTWILPTLLYRSCFHIICL  
VGTISLACNDMTPEQMATNVNCS<sup>25</sup>  
SPERHTRSVDYMEGGDIRVRRLF  
CRTQWYLRIKRGKVKGTQEMK  
N  
NYNIMEIRTVAVGIVAIGVSEF  
YLAMNKEGKLYAKKECNEDCNFK<sup>30</sup>  
ELILENHYNITYASAKWTHNGGEM  
FVALNQKGIPVRGKKTKEQKTA  
HFLPMAIT.

9. The KGF protein of any of claims 1 to 5, comprising a segment of amino acids of Figure II-1B which comprises amino acids 32 to 78 of Figure II-1B to confer on the KGF protein preferential mitogenic activity on an epithelial cell.

10. The KGF protein of any of claims 1 to 5, comprising a segment of the following amino acid sequence:

MHKWILTWILPTLLYRSCFHIICL  
VGTISLACNDMTPEQMATNVNCS<sup>45</sup>  
SPERHTRSVDYMEGGDIRVRRLF  
CRTQWYLRIKRGKVKGTQEMK  
N  
NYNIMEIRTVAVGIVAIGVSEF  
YLAMNKEGKLYAKKECNEDCNFK<sup>50</sup>  
ELILENHYNITYASAKWTHNGGEM  
FVALNQKGIPVRGKKTKEQKTA  
HFLPMAIT.

11. The KGF protein of claim 10, consisting of a segment of the following amino acid sequence:

MHKWILTWILPTLLYRSCFHIICL

VGTISLACNDMTPEQMATNVNCS  
SPERHTRSVDYMEGGDIRVRRLF  
CRTQWYLRIKRGKVKGTQEMK  
N  
NYNIMEIRTVAVGIVAIGVSEF  
YLAMNKEGKLYAKKECNEDCNFK  
ELILENHYNITYASAKWTHNGGEM  
FVALNQKGIPVRGKKTKEQKTA  
HFLPMAIT.

12. An isolated glycosylated or unglycosylated keratinocyte growth factor (KGF) protein according to any of claims 1 to 5 consisting of a segment of the following amino acid sequence:

CNDMTPEQMATNVNCS  
SPERHTRSVDYMEGGDIRVRRLF  
CRTQWYLRIKRGKVKGTQEMK  
N  
NYNIMEIRTVAVGIVAIGVSEF  
YLAMNKEGKLYAKKECNEDCNFK  
ELILENHYNITYASAKWTHNGGEM  
FVALNQKGIPVRGKKTKEQKTA  
HFLPMAIT,

wherein said segment has mitogenic activity for a keratinocyte cell, and wherein said segment may further include methionine at the amino terminus.

13. The KGF protein of claim 12 which has a specific activity of at least about  $3.4 \times 10^4$  units per milligram of protein, where one unit of activity is defined as that amount which causes half of the maximal possible stimulation of DNA synthesis in BALB/MK keratinocyte cells.

14. The KGF protein of any of claims 1 to 13, wherein said KGF protein comprises Met at the amino terminus.

15. A pharmaceutical composition comprising at least one KGF protein according to any of claims 1 to 14.

16. A pharmaceutical composition comprising at least one KGF protein according to any of claims 1 to 14 for stimulating epithelial cells.

17. Use of the KGF protein according to any of claims 1 to 14 for preparing a medicament for stimulating epithelial cells.

18. Use of the KGF protein according to any of claims 1 to 14 for preparing a medicament, wherein the medicament is to be topically applied to the skin or eye.

19. Use according to claim 18, wherein the medicament is to be topically applied to the skin.



20. A chimeric protein which comprises within a single polypeptide molecule a KGF protein of any of claims 1 to 14 and at least one other polypeptide portion of the fibroblast growth factor family.
21. The chimeric protein of claim 20, comprising amino acids 32 to 78 of Figure II-1B to confer on the polypeptide molecule preferential mitogenic activity of KGF for an epithelial cell.
22. The chimeric protein of claim 21, wherein the fibroblast growth factor is acidic fibroblast growth factor (aFGF).
23. The chimeric protein of claim 22, wherein the polypeptide portion of aFGF is defined by amino acid residues in that portion of aFGF that is homologous to the KGF sequence responsible for heparin sensitivity of KGF.
24. The chimeric protein according to claim 23, wherein the KGF protein is defined by amino acid residues numbered 32 through 78 in Figure II-1B and said polypeptide portion of aFGF is defined by the carboxyl terminus of aFGF, beginning at residue number 39.
25. A pharmaceutical composition comprising a chimeric protein according to any of claims 20 to 24, and a pharmaceutically acceptable carrier.
26. Use of a chimeric protein according to any of claims 20 to 24 for preparing a medicament for treating conditions requiring specific stimulation of epithelial cells in the presence of heparin.
27. Use of a chimeric protein according to any of claims 20 to 24 for preparing a medicament that is to be topically applied to the skin or eye.
28. An antibody specifically directed against KGF protein of any of claims 1 to 14.
29. The antibody of claim 28 which neutralizes the mitogenic activity of human KGF.
30. The antibody of claim 28 which is a polyclonal antibody.
31. The antibody of claim 28 which is a monoclonal antibody.
32. The antibody of claim 28 which reacts against the peptide NDMTPEQMATNVR.
33. A pharmaceutical composition comprising at least one antibody of claim 28 and a pharmaceutically acceptable carrier.
34. Use of the antibody of any of claims 28 to 32 for preparing a medicament for treating conditions requiring specific inhibition of stimulation of epithelial cells by KGF.
35. A recombinant DNA molecule encoding a keratinocyte growth factor (KGF) according to any of claims 1 to 14.
36. A recombinant DNA molecule which encodes a chimeric protein according to any of claims 20 to 24.
37. A recombinant DNA molecule comprising the DNA of any of claims 35 and 36 and a vector.
38. The recombinant DNA molecule of claim 37, wherein said vector is a plasmid, a bacteriophage cloning vector, a DNA sequencing plasmid vector, a bacterial gene expression vector, or a mammalian gene expression vector.
39. A host cell comprising a recombinant DNA molecule of any of claims 37 or 38.
40. The cell of claim 39 wherein said cell is a mammalian cell, an insect cell, a yeast cell, or a bacterial cell.
41. A method of producing KGF protein according to claim 1 comprising culturing the cell of any of claims 39 to 40 in a culture medium under conditions such that said protein is produced.
42. The method of claim 41 further comprising isolating the KGF protein.
43. The method of claim 41, wherein said recombinant DNA molecule comprises a promoter DNA other than the promoter DNA for the native KGF operatively linked to the DNA encoding the KGF protein.
44. A method of claim 43, wherein said recombinant DNA molecule comprises native DNA encoding the KGF protein.
45. The method of any of claims 41 to 44, wherein said cell is an *E. coli* cell.
46. A method of producing KGF protein or chimeric protein of any of claims 1 to 14, or 20 to 24 comprising the following steps:
  - i) contacting a first solution comprising said protein with heparin under conditions such that said protein binds to the heparin whereby a heparin-protein complex is formed;
  - ii) separating said heparin-protein complex

from said first solution; and

iii) dissociating said protein from the heparin-protein complex.

47. A method for determining the level of a KGF RNA transcript comprising the steps of:

i) isolating mRNA from tissues or cells;

ii) annealing said mRNA to a DNA probe encoding a KGF protein according to any of claims 1 to 14 to form a DNA:RNA hybrid; and

iii) determining the amount of said DNA:RNA hybrid.

48. A method for detecting a KGF protein in a sample comprising:

i) reacting polypeptides from body fluids or tissue samples with an antibody of claim 29 to form an antibody-polypeptide complex; and

ii) detecting said complex.

49. A composition comprising KGF protein or chimeric protein of any of claims 1 to 14, or 20 to 24.

50. A method of stimulating epithelial cell growth *in vitro* comprising adding an amount of the composition of claim 49 sufficient to stimulate epithelial cell growth.

51. The method of claim 50, wherein said cells are keratinocytes.

Claims for the following Contracting State : ES

1. A method for producing an isolated glycosylated or unglycosylated keratinocyte growth factor (KGF) protein comprising: (a) the following amino acid sequence, (b) a portion of the following amino acid sequence without the N-terminal 31 amino acids, or (c) an amino acid sequence that differs by the addition, deletion, or substitution of one or more amino acids from the following amino acid sequence:

MHKWILTWILPTLLYRSCFHIICL  
VGTISLACNDMTPEQMATNVNCS<sup>50</sup>  
SPERHTRSVDYMEGGDIRVRLF  
CRTQWYLRLDKRGKVKGTQEMK  
N  
NYNIMEIRTVAVGIVAIGVSEF  
YLAMNKEGKLYAKKECNEDCNFK<sup>55</sup>  
ELILENHYN TYASAKWTHNGGEM  
FVALNQKGIPVRGKKTKEQKTA  
HFLPMAIT

wherein said protein is capable of stimulating DNA synthesis in quiescent BALB/MK epidermal keratinocytes by more than 500-fold while lacking mitogenic activity on fibroblasts and endothelial cells, comprising culturing a host cell comprising a recombinant DNA molecule encoding said KGF protein under conditions such that said protein is produced.

2. The method of claim 1, wherein 5 nM of said protein exhibits less than one-fold stimulation over background in NIH/3T3 fibroblasts.

3. The method of any of claims 1 to 2 which has a specific activity of at least about  $3.4 \times 10^4$  units per milligram of protein, where one unit of activity is defined as that amount which causes half of the maximal possible stimulation of DNA synthesis in BALB/MK keratinocyte cells.

4. The method of any of claims 1 to 3 wherein said KGF protein is glycosylated.

5. The method of any of claims 1 to 3 wherein said KGF protein is not glycosylated.

6. The method of any of claims 1 to 5 wherein said KGF protein comprises the amino acid sequence:

CNDMTPEQMATNVNCS  
SPERHTRSVDYMEGGDIRVRLF  
CRTQWYLRLDKRGKVKGTQEMK  
N  
NYNIMEIRTVAVGIVAIGVSEF  
YLAMNKEGKLYAKKECNEDCNFK  
ELILENHYN TYASAKWTHNGGEM  
FVALNQKGIPVRGKKTKEQKTA  
HFLPMAIT.

7. The method of any of claims 1 to 5, wherein said KGF protein comprises an amino acid sequence differing by the addition, deletion, or substitution of one or more amino acids from the following amino acid sequence:

CNDMTPEQMATNVNCS  
SPERHTRSVDYMEGGDIRVRLF  
CRTQWYLRLDKRGKVKGTQEMK  
N  
NYNIMEIRTVAVGIVAIGVSEF  
YLAMNKEGKLYAKKECNEDCNFK  
ELILENHYN TYASAKWTHNGGEM  
FVALNQKGIPVRGKKTKEQKTA  
HFLPMAIT

8. The method of any of claims 1 to 5, wherein said KGF protein comprises an amino acid sequence

differing by the addition, deletion or substitution of one or more amino acids from the following amino acid sequence:

MHKWILTWILPTLLYRSCFHIICL 5  
VGTISLACNDMTPEQMATNVNCS  
SPERHTRSVDYMEGGDIRVRLF  
CRTQWYLRLDKRGKVKGTQEMK  
N  
NYNIMEIIRTVAVGIVAIGVSEF 10  
YLAMNKEGKLYAKKECNEDCNFK  
ELILENHNTYASAKWTHNGGEM  
FVALNQKGIPVRGKKTKEQKTA  
HFLPMAIT.

9. The method of any of claims 1 to 5, wherein said KGF protein comprises a segment of amino acids of Figure II-1B which comprises amino acids 32 to 78 of Figure II-1B to confer on the KGF protein preferential mitogenic activity on an epithelial cell.

10. The method of any of claims 1 to 5, wherein said KGF protein comprises a segment of the following amino acid sequence:

MHKWILTWILPTLLYRSCFHIICL  
VGTISLACNDMTPEQMATNVNCS  
SPERHTRSVDYMEGGDIRVRLF  
CRTQWYLRLDKRGKVKGTQEMK  
N  
NYNIMEIIRTVAVGIVAIGVSEF  
YLAMNKEGKLYAKKECNEDCNFK  
ELILENHNTYASAKWTHNGGEM  
FVALNQKGIPVRGKKTKEQKTA  
HFLPMAIT.

11. The method of claim 10, wherein said KGF protein consists of a segment of the following amino acid sequence:

MHKWILTWILPTLLYRSCFHIICL  
VGTISLACNDMTPEQMATNVNCS  
SPERHTRSVDYMEGGDIRVRLF  
CRTQWYLRLDKRGKVKGTQEMK  
N  
NYNIMEIIRTVAVGIVAIGVSEF  
YLAMNKEGKLYAKKECNEDCNFK  
ELILENHNTYASAKWTHNGGEM  
FVALNQKGIPVRGKKTKEQKTA  
HFLPMAIT.

12. A method for producing an isolated glycosylated or unglycosylated keratinocyte growth factor (KGF) protein according to any of claims 1 to 5 consisting of a segment of the following amino acid sequence:

CNDMTPEQMATNVNCS  
SPERHTRSVDYMEGGDIRVRLF

CRTQWYLRLDKRGKVKGTQEMK  
N  
NYNIMEIIRTVAVGIVAIGVSEF  
YLAMNKEGKLYAKKECNEDCNFK  
ELILENHNTYASAKWTHNGGEM  
FVALNQKGIPVRGKKTKEQKTA  
HFLPMAIT,

wherein said segment has mitogenic activity for a keratinocyte cell, and wherein said segment may further include methionine at the amino terminus, comprising culturing a host cell comprising a recombinant DNA molecule encoding said KGF protein under conditions such that said protein is produced.

13. The method of claim 12 wherein said KGF protein has a specific activity of at least about  $3.4 \times 10^4$  units per milligram of protein; where one unit of activity is defined as that amount which causes half of the maximal possible stimulation of DNA synthesis in BALB/MK keratinocyte cells.

14. The method of any of claims 1 to 13, wherein said KGF protein comprises Met at the amino terminus.

15. A method for producing a pharmaceutical composition comprising at least one KGF protein according to any of claims 1 to 14, comprising preparing said pharmaceutical composition in a manner known per se.

16. A method for producing a pharmaceutical composition comprising at least one KGF protein according to any of claims 1 to 14 for stimulating epithelial cells, comprising preparing said pharmaceutical composition in a manner known per se.

17. A method for preparing a medicament comprising a KGF protein according to any of claims 1 to 14, wherein the medicament is to be topically applied to the skin or eye, comprising preparing said medicament in a manner known per se.

18. The method according to claim 17, wherein the medicament is to be topically applied to the skin.

19. A method for producing a chimeric protein wherein said chimeric protein comprises within a single polypeptide molecule a KGF protein of any of claims 1 to 14 and at least one other polypeptide portion of the fibroblast growth factor family, comprising culturing a host cell comprising a recombinant DNA molecule encoding said chimeric protein under conditions such that said chimeric protein is produced.

20. The method of claim 19, wherein said chimeric pro-

tein comprises amino acids 32 to 78 of Figure II-1B to confer on the polypeptide molecule preferential mitogenic activity of KGF for an epithelial cell.

21. The method of claim 20, wherein the fibroblast growth factor is acidic fibroblast growth factor (aFGF). 5
22. The method of claim 21, wherein the polypeptide portion of aFGF is defined by amino acid residues in that portion of aFGF that is homologous to the KGF sequence responsible for heparin sensitivity of KGF. 10
23. The method according to claim 22, wherein the KGF protein is defined by amino acid residues numbered 32 through 78 in Figure II-1B and said polypeptide portion of aFGF is defined by the carboxyl terminus of aFGF, beginning at residue number 39. 15
24. A method for producing a pharmaceutical composition comprising a chimeric protein according to any of claims 19 to 23, and a pharmaceutically acceptable carrier, comprising preparing said pharmaceutical composition in a manner known per se. 20
25. A method for preparing a medicament for treating conditions requiring specific stimulation of epithelial cells in the presence of heparin, wherein said medicament comprises a chimeric protein according to any of claims 19 to 23, comprising preparing said medicament in a manner known per se. 25
26. A method for preparing a medicament that is to be topically applied to the skin or eye, wherein said medicament comprises a chimeric protein according to any of claims 19 to 23, comprising preparing said medicament in a manner known per se. 30
27. A method for producing an antibody specifically directed against KGF protein of any of claims 1 to 14, comprising culturing a host cell comprising a recombinant DNA molecule encoding said antibody under conditions such that said antibody is produced. 35
28. The method of claim 27 wherein said antibody neutralizes the mitogenic activity of human KGF. 40
29. The method of claim 27 wherein said antibody is a polyclonal antibody. 45
30. The method of claim 27 wherein said antibody is a monoclonal antibody. 50
31. The method of claim 27 wherein said antibody reacts against the peptide NDMTPEQMATNVR. 55
32. A method for preparing a pharmaceutical composition comprising at least one antibody of claim 27 and a pharmaceutically acceptable carrier, comprising preparing said pharmaceutical composition in a manner known per se.
33. A method for preparing a medicament for treating conditions requiring specific inhibition of stimulation of epithelial cells by KGF, wherein said medicament comprises the antibody of any of claims 27 to 31, comprising preparing said medicament in a manner known per se.
34. A method for producing a recombinant DNA molecule encoding a keratinocyte growth factor (KGF) according to any of claims 1 to 14, comprising constructing said recombinant DNA molecule in a manner known per se.
35. A method for producing a recombinant DNA molecule which encodes a chimeric protein according to any of claims 19 to 23, comprising constructing said recombinant DNA molecule in a manner known per se.
36. A method for producing a recombinant DNA molecule comprising the DNA of any of claims 34 and 35 and a vector, comprising constructing said recombinant DNA molecule in a manner known per se.
37. The method of claim 36, wherein said vector is a plasmid, a bacteriophage cloning vector, a DNA sequencing plasmid vector, a bacterial gene expression vector, or a mammalian gene expression vector.
38. A method for producing a host cell comprising a recombinant DNA molecule of any of claims 36 or 37, comprising transforming a host cell with said recombinant DNA molecule.
39. The method of claim 38 wherein said cell is a mammalian cell, an insect cell, a yeast cell, or a bacterial cell.
40. A method of producing KGF protein according to claim 1 comprising culturing the cell of any of claims 38 to 39 in a culture medium under conditions such that said protein is produced.
41. The method of claim 40 further comprising isolating the KGF protein.
42. The method of claim 40, wherein said recombinant DNA molecule comprises a promoter DNA other than the promoter DNA for the native KGF operatively linked to the DNA encoding the KGF protein.

43. The method of claim 42, wherein said recombinant DNA molecule comprises native DNA encoding the KGF protein.

44. The method of any of claims 40 to 43, wherein said cell is an *E. coli* cell.

45. A method of producing KGF protein or chimeric protein of any of claims 1 to 14, or 19 to 23 comprising the following steps:

i) contacting a first solution comprising said protein with heparin under conditions such that said protein binds to the heparin whereby a heparin-protein complex is formed;

ii) separating said heparin-protein complex from said first solution; and

iii) dissociating said protein from the heparin-protein complex.

46. A method for determining the level of a KGF RNA transcript comprising the steps of:

i) isolating mRNA from tissues or cells;

ii) annealing said mRNA to a DNA probe encoding a KGF protein according to any of claims 1 to 14 to form a DNA:RNA hybrid; and

iii) determining the amount of said DNA:RNA hybrid.

47. A method for detecting a KGF protein in a sample comprising:

i) reacting polypeptides from body fluids or tissue samples with an antibody of claim 28 to form an antibody-polypeptide complex; and  
ii) detecting said complex.

48. A method for producing a composition comprising KGF protein or chimeric protein of any of claims 1 to 14, or 19 to 23, comprising producing said composition in a manner known per se.

49. A method of stimulating epithelial cell growth *in vitro* comprising adding an amount of the composition of claim 48 sufficient to stimulate epithelial cell growth.

50. The method of claim 49, wherein said cells are keratinocytes.

## Patentansprüche

Patentansprüche für folgende Vertragsstaaten : AT, BE, CH, LI, DE, DK, FR, GB, IT, LU, NL, SE

1. Isoliertes, glykosyliertes oder nicht-glykosyliertes Keratinocytenwachstumsfaktor (KGF)-Protein, umfassend:

(a) die nachstehende Aminosäuresequenz,

(b) einen Teil der nachstehenden Aminosäuresequenz ohne die N-terminalen 31 Aminosäuren oder

(c) eine Aminosäuresequenz, die sich durch die Addition, Deletion oder Substitution einer oder mehrerer Aminosäuren von der nachstehenden Aminosäuresequenz unterscheidet:

```
MHKWILTWILPTLLYRSCFHI
ICL
VGTISLACNDMTPEQMATNV
NCS
SPERHTRS DYMEGGDIRVR
RLF
CRTQWYLRIKRGKVKGTQE
MKN
NYNIMEIRTVAVGIVAIGVE
SEF
YLAMNKEGKLYAKKECNEDC
NFK
ELILENHNTYASAKWTHNG
GEM
FVALNQKGIPVRGKKTKEQ
KTA
HFLPMAIT,
```

worin das Protein fähig ist, die DNA-Synthese in ruhenden BALB/MK epidermalen Keratinocyten mehr als 500-fach zu stimulieren, wohingegen das Protein keine mitogene Aktivität auf Fibroblasten und Endothel-Zellen aufweist.

2. KGF-Protein gemäß Anspruch 1, wobei 5 nM Protein weniger als einfache Stimulierung in NIH/3T3 Fibroblasten gegenüber dem Hintergrund aufweist.

3. KGF-Protein gemäß einem der Ansprüche 1 - 2, wobei das KGF-Protein eine spezifische Aktivität von wenigstens ungefähr  $3,4 \times 10^4$  Einheiten pro Milligramm Protein aufweist, wobei eine Aktivitätseinheit definiert ist als die Menge, die die Hälfte der maximal möglichen Stimulierung der DNA-Synthese in BALB/MK Keratinocytenzellen hervorruft.

4. KGF-Protein gemäß einem der Ansprüche 1 - 3, wobei das KGF-Protein glykosyliert ist.

5. KGF-Protein gemäß einem der Ansprüche 1 - 3, wobei das KGF-Protein nicht glykosyliert ist.

6. KGF-Protein gemäß einem der Ansprüche 1 - 5, das die Aminosäuresequenz umfasst:

CNDMTPEQMATNVNCS  
SPERHTRSVDYMEGGDIRVRRFL  
CRTQWYLRIKRGKVKGTQEMK  
N  
NYNIMEIRTVAVGIVAIGVESEF  
YLAMNKEGKLYAKKECNEDCNFK  
ELILENHYNITYASAKWTHNGGEM  
FVALNQKGIPVRGKKTKEQKTA  
HFLPMAIT.

7. KGF-Protein gemäß einem der Ansprüche 1 - 5, das eine Aminosäuresequenz umfasst, die sich durch die Addition, Deletion oder Substitution einer oder mehrerer Aminosäuren von der nachstehenden Aminosäuresequenz unterscheidet:

CNDMTPEQMATNVNCS  
SPERHTRSVDYMEGGDIRVRRFL  
CRTQWYLRIKRGKVKGTQEMK  
N  
NYNIMEIRTVAVGIVAIGVESEF  
YLAMNKEGKLYAKKECNEDCNFK  
ELILENHYNITYASAKWTHNGGEM  
FVALNQKGIPVRGKKTKEQKTA  
HFLPMAIT

8. KGF-Protein gemäß einem der Ansprüche 1 - 5, das eine Aminosäuresequenz umfasst, die sich durch die Addition, Deletion oder Substitution einer oder mehrerer Aminosäuren von der nachstehenden Aminosäuresequenz unterscheidet:

MHKWILTWILPTLLYRSCFHIICL  
VGTISLACNDMTPEQMATNVNCS  
SPERHTRSVDYMEGGDIRVRRFL  
CRTQWYLRIKRGKVKGTQEMK  
N  
NYNIMEIRTVAVGIVAIGVESEF  
YLAMNKEGKLYAKKECNEDCNFK  
ELILENHYNITYASAKWTHNGGEM  
FVALNQKGIPVRGKKTKEQKTA  
HFLPMAIT.

9. KGF-Protein gemäß einem der Ansprüche 1 - 5, das einen Aminosäurenabschnitt von Figur II-1B umfasst, der die Aminosäuren 32 - 78 von Figur II-1B umfasst, um dem KGF-Protein bevorzugte mitogene Aktivität für eine Epithelzelle zu übertragen.

10. KGF-Protein gemäß einem der Ansprüche 1 - 5, das einen Abschnitt der nachstehenden Aminosäuresequenz umfasst:

MHKWILTWILPTLLYRSCFHIICL  
VGTISLACNDMTPEQMATNVNCS  
SPERHTRSVDYMEGGDIRVRRFL  
CRTQWYLRIKRGKVKGTQEMK  
N  
NYNIMEIRTVAVGIVAIGVESEF  
YLAMNKEGKLYAKKECNEDCNFK  
ELILENHYNITYASAKWTHNGGEM  
FVALNQKGIPVRGKKTKEQKTA  
HFLPMAIT.

11. KGF-Protein gemäß Anspruch 10, das aus einem Abschnitt der nachstehenden Aminosäuresequenz besteht:

MHKWILTWILPTLLYRSCFHIICL  
VGTISLACNDMTPEQMATNVNCS  
SPERHTRSVDYMEGGDIRVRRFL  
CRTQWYLRIKRGKVKGTQEMK  
N  
NYNIMEIRTVAVGIVAIGVESEF  
YLAMNKEGKLYAKKECNEDCNFK  
ELILENHYNITYASAKWTHNGGEM  
FVALNQKGIPVRGKKTKEQKTA  
HFLPMAIT.

12. Isoliertes, glykosyliertes oder nicht-glykosyliertes Keratinocytenwachstumsfaktor (KGF)-Protein gemäß einem der Ansprüche 1 - 5, das aus einem Abschnitt der nachstehenden Aminosäuresequenz besteht:

CNDMTPEQMATNVNCS  
SPERHTRSVDYMEGGDIRVRRFL  
CRTQWYLRIKRGKVKGTQEMK  
N  
NYNIMEIRTVAVGIVAIGVESEF  
YLAMNKEGKLYAKKECNEDCNFK  
ELILENHYNITYASAKWTHNGGEM  
FVALNQKGIPVRGKKTKEQKTA  
HFLPMAIT,

worin der Abschnitt mitogene Aktivität für eine Keratinocytenzelle aufweist, und wobei der Abschnitt weiterhin Methionin am Amino-Terminus umfassen kann.

13. KGF-Protein gemäß Anspruch 12, wobei das KGF-Protein eine spezifische Aktivität von wenigstens ungefähr  $3,4 \times 10^4$  Einheiten pro Milligramm Protein aufweist, worin eine Aktivitätseinheit definiert ist als die Menge, die die Hälfte der maximal möglichen Stimulierung der DNA-Synthese in BALB/MK Keratinocytenzellen hervorruft.

14. KGF-Protein gemäß einem der Ansprüche 1 - 13, worin das KGF-Protein Met am Amino-Terminus umfasst.



15. Pharmazeutische Zusammensetzung, die wenigstens ein KGF-Protein gemäß einem der Ansprüche 1 - 14 umfasst.
16. Pharmazeutische Zusammensetzung zur Stimulierung von Epithelzellen, die wenigstens ein KGF-Protein gemäß einem der Ansprüche 1 - 14 umfasst.
17. Verwendung des KGF-Proteins gemäß einem der Ansprüche 1 - 14 zum Herstellen eines Medikaments zur Stimulierung von Epithelzellen.
18. Verwendung des KGF-Proteins gemäß einem der Ansprüche 1 - 14 zum Herstellen eines Medikaments, worin das Medikament topisch auf die Haut oder das Auge aufgebracht wird.
19. Verwendung des KGF-Proteins gemäß Anspruch 18, worin das Medikament topisch auf die Haut aufgebracht wird.
20. Chimäres Protein, wobei das chimäre Protein innerhalb eines einzelnen Polypeptidmoleküls ein KGF-Protein gemäß einem der Ansprüche 1 - 14 und wenigstens einen weiteren Teil eines Polypeptides der Fibroblastenwachstumsfaktor-Familie umfasst.
21. Chimäres Protein gemäß Anspruch 20, das die Aminosäuren 32 bis 78 von Figur II-1B umfasst, um dem Polypeptidmolekül bevorzugte mitogene Aktivität von KGF für eine Epithelzelle zu übertragen.
22. Chimäres Protein gemäß Anspruch 21, worin der Fibroblastenwachstumsfaktor der saure Fibroblastenwachstumsfaktor (aFGF) ist.
23. Chimäres Protein gemäß Anspruch 22, worin der Teil eines Polypeptides von aFGF durch die Aminosäurereste in dem Teil von aFGF bestimmt ist, der homolog zu der für die Heparinsensitivität von KGF verantwortlichen KGF-Sequenz ist.
24. Chimäres Protein gemäß Anspruch 23, worin das KGF-Protein durch die Aminosäurereste 32 - 78 in Figur II-1B bestimmt ist und der Teil eines Polypeptides von aFGF durch den Carboxy-Terminus von aFGF bestimmt ist, der mit dem Aminosäurerest 39 beginnt.
25. Pharmazeutische Zusammensetzung, die ein chimäres Protein gemäß einem der Ansprüche 20 - 24 und einen pharmazeutisch verträglichen Träger umfasst.
26. Verwendung eines chimären Proteins gemäß einem der Ansprüche 20 - 24 zum Herstellen eines
- Medikamentes zum Behandeln von Zuständen, die die spezifische Stimulierung von Epithelzellen in Gegenwart von Heparin erfordern.
27. Verwendung eines chimären Proteins gemäß einem der Ansprüche 20 - 24 zum Herstellen eines Medikamentes, das topisch auf die Haut oder das Auge aufgebracht wird.
28. Antikörper, der spezifisch gegen das KGF-Protein gemäß einem der Ansprüche 1 - 14 gerichtet ist.
29. Antikörper gemäß Anspruch 28, der die mitogene Aktivität von humanem KGF neutralisiert.
30. Antikörper gemäß Anspruch 28, der ein polyklonaler Antikörper ist.
31. Antikörper gemäß Anspruch 28, der ein monoklonaler Antikörper ist.
32. Antikörper gemäß Anspruch 28, der mit dem Peptid NDMTPEQMATNVR reagiert.
33. Pharmazeutische Zusammensetzung, die wenigstens einen Antikörper gemäß Anspruch 28 und einen pharmazeutisch verträglichen Träger umfasst.
34. Verwendung des Antikörpers gemäß einem der Ansprüche 28 - 32 zum Herstellen eines Medikamentes zum Behandeln von Zuständen, die die spezifische Hemmung der Stimulierung von Epithelzellen durch KGF erfordern.
35. Rekombinantes DNA-Molekül, das einen Keratinozytenwachstumsfaktor (KGF) gemäß einem der Ansprüche 1 - 14 kodiert.
36. Rekombinantes DNA-Molekül, das ein chimäres Protein gemäß einem der Ansprüche 20 - 24 kodiert.
37. Rekombinantes DNA-Molekül, das das DNA-Molekül gemäß einem der Ansprüche 35 und 36 und einen Vektor umfasst.
38. Rekombinantes DNA-Molekül gemäß Anspruch 37, worin der Vektor ein Plasmid, ein Bakteriophagen-Klonierungsvektor, ein DNA-Sequenzierungs-Plasmidvektor, ein Genexpressionsvektor in Bakterien oder ein Genexpressionsvektor in Säugern ist.
39. Wirtszelle, die ein rekombinantes DNA-Molekül gemäß einem der Ansprüche 37 oder 38 umfasst.
40. Zelle gemäß Anspruch 39, worin die Zelle eine Säugerzelle, eine insektenzelle, eine Hefezelle,

oder eine Bakterienzelle ist.

41. Verfahren zum Herstellen des KGF-Proteins gemäß Anspruch 1, wobei das Verfahren den Schritt des Kultivierens der Zelle gemäß einem der Ansprüche 39 - 40 in einem Kulturmedium unter Bedingungen umfasst, so dass das Protein hergestellt wird. 5
42. Verfahren gemäß Anspruch 41, das weiterhin den Schritt des Isolierens des KGF-Proteins umfasst. 10
43. Verfahren gemäß Anspruch 41, worin das rekombinante DNA-Molekül eine von der natürlichen KGF-Promotor-DNA unterschiedliche Promotor-DNA umfasst, die in operativer Weise mit der das KGF-Protein kodierenden DNA verbunden ist. 15
44. Verfahren gemäß Anspruch 43, worin das rekombinante DNA-Molekül KGF-Protein kodierende natürliche DNA umfasst. 20
45. Verfahren gemäß einem der Ansprüche 41 - 44, worin die Zelle eine *E. coli* Zelle ist. 25
46. Verfahren zum Herstellen des KGF-Proteins oder des chimären Proteins gemäß einem der Ansprüche 1 - 14 oder 20 - 24, das die nachstehenden Schritte umfasst: 30
  - i) Inkontaktbringen einer ersten das Protein umfassenden Lösung mit Heparin unter Bedingungen, so dass das Protein an das Heparin bindet, wodurch ein Heparin-Proteinkomplex gebildet wird; 35
  - ii) Abtrennen des Heparin-Proteinkomplexes aus der ersten Lösung; und
  - iii) Abtrennen des Proteins aus dem Heparin-Proteinkomplex. 40
47. Verfahren zum Bestimmen des Spiegels an KGF-RNA-Transkript, wobei das Verfahren die Schritte umfasst: 45
  - i) Isolieren der mRNA aus Geweben oder Zellen;
  - ii) Anlagern (annealing) der mRNA an eine DNA-Sonde, die ein KGF-Protein gemäß einem der Ansprüche 1 - 14 kodiert, zur Bildung eines DNA:RNA-Hybrids; und 50
  - iii) Bestimmen der Menge von DNA:RNA-Hybrid. 55
48. Verfahren zum Nachweisen eines KGF-Proteins in einer Probe, wobei das Verfahren die Schritte umfasst:

i) Umsetzen von Polypeptiden aus Körperflüssigkeiten oder Gewebeproben mit einem Antikörper gemäß Anspruch 29 zur Bildung eines Antikörper-Polypeptidkomplexes; und

ii) Nachweisen des Komplexes.

49. Zusammensetzung, die das KGF-Protein oder chimäres Protein gemäß einem der Ansprüche 1 - 14 oder 20 - 24 umfasst.

50. Verfahren zur Stimulierung des Epithelzellwachstums *in vitro*, wobei das Verfahren den Schritt des Hinzufügens einer für die Stimulierung des Epithelzellwachstums ausreichenden Menge der Zusammensetzung gemäß Anspruch 49 umfasst.

51. Verfahren gemäß Anspruch 50, worin die Zellen Keratinocyten sind.

#### Patentansprüche für folgenden Vertragsstaat : ES

1. Verfahren zum Herstellen eines isolierten, glykosylierten oder nicht-glykosylierten Keratinocytenwachstumsfaktor (KGF)-Proteins, umfassend:

- a) die nachstehende Aminosäuresequenz,
- b) einen Teil der nachstehenden Aminosäuresequenz ohne die N-terminalen 31 Aminosäuren oder
- c) eine Aminosäuresequenz, die sich durch die Addition, Deletion oder Substitution einer oder mehrerer Aminosäuren von der nachstehenden Aminosäuresequenz unterscheidet:

MHKWILTWILPTLLYRSCFHI  
ICL  
VGTISLACNDMTPEQMATNV  
NCS  
SPERHTRSYDYMEGGDIRVR  
RLF  
CRTQWYLRIKRGKVKGTQE  
MKN  
NYNIMEIRTVAVGIVAIGVE  
SEF  
YLAMNKEGKLYAKKECNEDC  
NFK  
ELILENHNTYASAKWTHNG  
GEM  
FVALNQKGIPVRGKKTKEQ  
KTA  
HFLPMAIT,

worin das Protein fähig ist, die DNA-Synthese in ruhenden BALB/MK epidermalen Keratinocyten mehr als 500-fach zu stimulieren, wohin-

gegen das Protein keine mitogene Aktivität auf Fibroblasten und Endothel-Zellen aufweist, umfassend das Kultivieren einer Wirtszelle, die ein das KGF-Protein kodierendes rekombinantes DNA-Molekül umfasst, unter Bedingungen, so dass das Protein hergestellt wird.

2. Verfahren gemäß Anspruch 1, wobei 5 nM Protein weniger als einfache Stimulierung in NIH/3T3 Fibroblasten gegenüber dem Hintergrund aufweist, umfassend das Kultivieren einer Wirtszelle, die ein das KGF-Protein kodierendes rekombinantes DNA-Molekül umfasst, unter Bedingungen, so dass das Protein hergestellt wird.
3. Verfahren gemäß einem der Ansprüche 1 bis 2, wobei das KGF-Protein eine spezifische Aktivität von wenigstens ungefähr  $3,4 \times 10^4$  Einheiten pro Milligramm Protein aufweist, wobei eine Aktivitätseinheit definiert ist als die Menge, die die Hälfte der maximal möglichen Stimulierung der DNA-Synthese in BALB/MK Keratinocytenzellen hervorruft.
4. Verfahren gemäß einem der Ansprüche 1 - 3, wobei das KGF-Protein glykosyliert ist.
5. Verfahren gemäß einem der Ansprüche 1 - 3, wobei das KGF-Protein nicht-glykosyliert ist.
6. Verfahren gemäß einem der Ansprüche 1 - 5, wobei das KGF-Protein die Aminosäuresequenz umfasst:

CNDMTPEQMATNVNCS  
SPERHTRS DYMEGGDIRVRRLF  
CRTQWYLRI DKGKVKGTQEMK  
N  
NYNIMEIRTVA VGIVA IKGVESEF  
YLAMNKEGKLYAKKECNEDCNFK  
ELILENHYN TYASAKWTHNGGEM  
FVALNQKGIPVRGKKTKEQKTA  
HFLPMAIT.

7. Verfahren gemäß einem der Ansprüche 1 - 5, wobei das KGF-Protein eine Aminosäuresequenz umfasst, die sich durch die Addition, Deletion oder Substitution einer oder mehrerer Aminosäuren von der nachstehenden Aminosäuresequenz unterscheidet:

CNDMTPEQMATNVNCS  
SPERHTRS DYMEGGDIRVRRLF  
CRTQWYLRI DKGKVKGTQEMK  
N  
NYNIMEIRTVA VGIVA IKGVESEF  
YLAMNKEGKLYAKKECNEDCNFK  
ELILENHYN TYASAKWTHNGGEM  
FVALNQKGIPVRGKKTKEQKTA  
HFLPMAIT.

8. Verfahren gemäß einem der Ansprüche 1 - 5, wobei das KGF-Protein eine Aminosäuresequenz umfasst, die sich durch die Addition, Deletion oder Substitution einer oder mehrerer Aminosäuren von der nachstehenden Aminosäuresequenz unterscheidet:

MHKWILTWILPTLLYRSCFHIICL  
VGTISLACNDMTPEQMATNVNCS  
SPERHTRS DYMEGGDIRVRRLF  
CRTQWYLRI DKGKVKGTQEMK  
N  
NYNIMEIRTVA VGIVA IKGVESEF  
YLAMNKEGKLYAKKECNEDCNFK  
ELILENHYN TYASAKWTHNGGEM  
FVALNQKGIPVRGKKTKEQKTA  
HFLPMAIT

9. Verfahren gemäß einem der Ansprüche 1-5, wobei das KGF-Protein einen Aminosäurenabschnitt von Figur II-1B umfasst, der die Aminosäuren 32-78 von Figur II-16 umfasst, um dem KGF-Protein bevorzugte mitogene Aktivität für eine Epithelzelle zu übertragen.

10. Verfahren gemäß einem der Ansprüche 1-5, wobei das KGF-Protein einen Abschnitt der nachstehenden Aminosäuresequenz umfasst:

MHKWILTWILPTLLYRSCFHIICL  
VGTISLACNDMTPEQMATNVNCS  
SPERHTRS DYMEGGDIRVRRLF  
CRTQWYLRI DKGKVKGTQEMK  
N  
NYNIMEIRTVA VGIVA IKGVESEF  
YLAMNKEGKLYAKKECNEDCNFK  
ELILENHYN TYASAKWTHNGGEM  
FVALNQKGIPVRGKKTKEQKTA  
HFLPMAIT.

11. Verfahren gemäß Anspruch 10, wobei das KGF-Protein aus einem Abschnitt der nachstehenden Aminosäuresequenz besteht:

MHKWILTWILPTLLYRSCFHIICL  
VGTISLACNDMTPEQMATNVNCS  
SPERHTRS DYMEGGDIRVRRLF  
CRTQWYLRI DKGKVKGTQEMK  
N  
NYNIMEIRTVA VGIVA IKGVESEF  
YLAMNKEGKLYAKKECNEDCNFK  
ELILENHYN TYASAKWTHNGGEM  
FVALNQKGIPVRGKKTKEQKTA  
HFLPMAIT.

12. Verfahren zum Herstellen isolierten, glykosylierten oder nicht-glykosylierten Keratinocytenwachstumsfaktor (KGF)-Proteins gemäß einem der Ansprüche

1-5, wobei das KGF-Protein aus einem Abschnitt der nachstehenden Aminosäuresequenz besteht:

CNDMTPEQMATNVNCS  
SPERHTRS DYMEGGDIRVRLFS  
CRTQWYLRI DKRGKVKGTEMK  
N  
NYNIMEIRTVAVGIVAIGVESEF  
YLAMNKEGKLYAKKECNE DCNFK  
ELILENHNTYASAKWTHNGGEM<sup>10</sup>  
FVALNQKGIPVRGKKTKEQKTA  
HFLPMAIT,

worin der Abschnitt mitogene Aktivität für eine Keratinocytenzelle aufweist, und wobei der Abschnitt weiterhin Methionin am Amino-Terminus umfassen kann, umfassend das Kultivieren einer Wirtszelle, die ein das KGF-Protein kodierendes rekombinantes DNA-Molekül umfasst, unter Bedingungen, so dass das Protein hergestellt wird.

13. Verfahren gemäß Anspruch 12, wobei das KGF-Protein eine spezifische Aktivität von wenigstens ungefähr  $3,4 \times 10^4$  Einheiten pro Milligramm Protein aufweist, worin eine Aktivitätseinheit definiert ist als die Menge, die die Hälfte der maximal möglichen Stimulierung der DNA-Synthese in BALB/MK Keratinocytenzellen hervorruft.

14. Verfahren gemäß einem der Ansprüche 1-14, worin das KGF-Protein Met am Amino-Terminus umfasst.

15. Verfahren zum Herstellen einer pharmazeutischen Zusammensetzung, die wenigstens ein KGF-Protein gemäß einem der Ansprüche 1-14 umfasst, wobei das Verfahren das Herstellen der pharmazeutischen Zusammensetzung in an sich bekannter Weise umfasst.

16. Verfahren zum Herstellen einer pharmazeutischen Zusammensetzung, umfassend wenigstens ein KGF-Protein gemäß einem der Ansprüche 1-14 zur Stimulierung von Epithelzellen, wobei das Verfahren das Herstellen der pharmazeutischen Zusammensetzung in an sich bekannter Weise umfasst.

17. Verfahren zum Herstellen eines Medikamentes, umfassend ein KGF-Protein gemäß einem der Ansprüche 1-14, worin das Medikament topisch auf die Haut oder das Auge aufgebracht wird, und wobei das Verfahren das Herstellen des Medikamentes in an sich bekannter Weise umfasst.

18. Verfahren gemäß Anspruch 17, worin das Medikament topisch auf die Haut aufgebracht wird.

19. Verfahren zum Herstellen eines chimären Proteins,

wobei das chimäre Protein innerhalb eines einzelnen Polypeptidmoleküls ein KGF-Protein gemäß einem der Ansprüche 1-14 und wenigstens einen weiteren Teil eines Polypeptides der Fibroblastenwachstumsfaktor-Familie umfasst, wobei das Verfahren das Kultivieren einer Wirtszelle, die ein das chimäre Protein kodierendes rekombinantes DNA-Molekül umfasst unter Bedingungen, so dass das Protein hergestellt wird, umfasst.

20. Verfahren gemäß Anspruch 19, wobei das chimäre Protein die Aminosäuren 32 bis 78 von Figur II-1B umfasst, um dem Polypeptidmolekül bevorzugte mitogene Aktivität von KGF für eine Epithelzelle zu übertragen.

21. Verfahren gemäß Anspruch 20, worin der Fibroblastenwachstumsfaktor der saure Fibroblastenwachstumsfaktor (aFGF).

22. Verfahren gemäß Anspruch 21, worin der Teil eines Polypeptides von aFGF durch die Aminosäurereste in dem Teil von aFGF bestimmt ist, der homolog zu der für die Heparinsensitivität von KGF verantwortlichen KGF-Sequenz ist.

23. Verfahren gemäß Anspruch 22, worin das KGF-Protein durch die Aminosäurereste 32 - 78 in Figur II-1B bestimmt ist und der Teil eines Polypeptides von aFGF durch den Carboxy-Terminus von aFGF bestimmt ist, der mit dem Aminosäurerest 39 beginnt.

24. Verfahren zum Herstellen einer pharmazeutischen Zusammensetzung, umfassend ein chimäres Protein gemäß einem der Ansprüche 19 - 23 und einen pharmazeutisch verträglichen Träger, wobei das Verfahren das Herstellen der pharmazeutischen Zusammensetzung in an sich bekannter Weise umfasst.

25. Verfahren zum Herstellen eines Medikamentes zum Behandeln von Zuständen, die die spezifische Stimulierung von Epithelzellen in Gegenwart von Heparin erfordern, wobei das Medikament ein chimäres Protein gemäß einem der Ansprüche 19 - 23 umfasst und wobei das Verfahren das Herstellen des Medikamentes in an sich bekannter Weise umfasst.

26. Verfahren zum Herstellen eines Medikamentes, das topisch auf die Haut oder das Auge aufgebracht wird, wobei das Medikament ein chimäres Protein gemäß einem der Ansprüche 19 - 23 umfasst, und wobei das Verfahren das Herstellen des Medikamentes in an sich bekannter Weise umfasst.

27. Verfahren zum Herstellen eines Antikörpers, der spezifisch gegen das KGF-Protein gemäß einem der Ansprüche 1 - 14 gerichtet ist, wobei das Verfahren das Kultivieren einer Wirtszelle, die ein den Antikörper kodierendes rekombinantes DNA-Molekül umfasst, unter Bedingungen, so dass das Protein hergestellt wird, umfasst. 5
28. Verfahren gemäß Anspruch 27, wobei der Antikörper die mitogene Aktivität von humanem KGF neutralisiert. 10
29. Verfahren gemäß Anspruch 27, wobei der Antikörper ein polyklonaler Antikörper ist. 15
30. Verfahren gemäß Anspruch 27, wobei der Antikörper ein monoklonaler Antikörper ist.
31. Verfahren gemäß Anspruch 27, wobei der Antikörper mit dem Peptid NDMTPEQMATNVR reagiert. 20
32. Verfahren zum Herstellen einer pharmazeutischen Zusammensetzung, die wenigstens einen Antikörper gemäß Anspruch 27 und einen pharmazeutisch verträglichen Träger umfasst, und wobei das Verfahren das Herstellen der pharmazeutischen Zusammensetzung in an sich bekannter Weise umfasst. 25
33. Verfahren zum Herstellen eines Medikamentes zum Behandeln von Zuständen, die die spezifische Hemmung der Stimulierung von Epithelzellen von KGF erfordern, wobei das Medikament den Antikörper gemäß einem der Ansprüche 27 - 31 umfasst, und wobei das Verfahren das Herstellen des Medikamentes in an sich bekannter Weise umfasst. 30
34. Verfahren zum Herstellen eines rekombinanten DNA-Moleküls, das einen Keratinocytenwachstumsfaktor (KGF) gemäß einem der Ansprüche 1 - 14 kodiert, wobei das Verfahren das Herstellen des rekombinanten DNA-Moleküls in an sich bekannter Weise umfasst. 40
35. Verfahren zum Herstellen eines rekombinanten DNA-Moleküls, das ein chimäres Protein gemäß einem der Ansprüche 19 - 23 kodiert, und wobei das Verfahren das Herstellen des rekombinanten DNA-Moleküls in an sich bekannter Weise umfasst. 45
36. Verfahren zum Herstellen eines rekombinanten DNA-Moleküls, dass das DNA-Molekül gemäß einem der Ansprüche 34 und 35 und einen Vektor umfasst, und wobei das Verfahren das Herstellen des rekombinanten DNA-Moleküls in an sich bekannter Weise umfasst. 50
37. Verfahren zum Herstellen eines rekombinanten DNA-Moleküls gemäß Anspruch 36, worin der Vektor ein Plasmid, ein Bakteriophagen-Klonierungsvektor, ein DNA-Sequenzierungs-Plasmidvektor, ein Genexpressionsvektor in Bakterien oder ein Genexpressionsvektor in Säugern ist.
38. Verfahren zum Herstellen einer Wirtszelle, die ein rekombinantes DNA-Molekül gemäß einem der Ansprüche 36 oder 37 umfasst, und wobei das Verfahren das Transformieren einer Wirtszelle mit dem rekombinanten DNA-Molekül umfasst.
39. Verfahren gemäß Anspruch 38, worin die Zelle eine Säugerzelle, eine Insektenzelle, eine Hefezelle, oder eine Bakterienzelle ist. 15
40. Verfahren zum Herstellen des KGF-Proteins gemäß Anspruch 1, wobei das Verfahren den Schritt des Kultivierens der Zelle gemäß einem der Ansprüche 38 - 39 in einem Kulturmedium unter Bedingungen umfasst, so dass das Protein hergestellt wird.
41. Verfahren gemäß Anspruch 40, das weiterhin den Schritt des Isolierens des KGF-Proteins umfasst.
42. Verfahren gemäß Anspruch 40, worin das rekombinante DNA-Molekül eine von der natürlichen KGF-Promotor-DNA unterschiedliche Promotor-DNA umfasst, die in operativer Weise mit der das KGF-Protein kodierenden DNA verbunden ist.
43. Verfahren gemäß Anspruch 42, worin das rekombinante DNA-Molekül KGF-Protein kodierende natürliche DNA umfasst. 35
44. Verfahren gemäß einem der Ansprüche 40 - 43, worin die Zelle eine *E. coli* Zelle ist.
45. Verfahren zum Herstellen des KGF-Proteins oder des chimären Proteins gemäß einem der Ansprüche 1 - 14 oder 19 - 23, das die nachstehenden Schritte umfasst:
- i) Inkontaktbringen einer ersten das Protein umfassenden Lösung mit Heparin unter Bedingungen, so dass das Protein an das Heparin bindet, wodurch ein Heparin-Proteinkomplex gebildet wird;
  - ii) Abtrennen des Heparin-Proteinkomplexes aus der ersten Lösung; und
  - iii) Abtrennen des Proteins aus dem Heparin-Proteinkomplex.
46. Verfahren zum Bestimmen des Spiegels an KGF-RNA-Transkript, wobei das Verfahren die Schritte

umfasst:

i) Isolieren der mRNA aus Geweben oder Zellen;

ii) Anlagern (annealing) der mRNA an eine DNA-Sonde, die ein KGF-Protein gemäß einem der Ansprüche 1 - 14 kodiert, zur Bildung eines DNA:RNA-Hybrids; und

iii) Bestimmen der Menge von DNA:RNA-Hybrid.

47. Verfahren zum Nachweisen eines KGF-Proteins in einer Probe, wobei das Verfahren die Schritte umfasst:

i) Umsetzen von Polypeptiden aus Körperflüssigkeiten oder Gewebeproben mit einem Antikörper gemäß Anspruch 28 zur Bildung eines Antikörper-Polypeptidkomplexes; und

ii) Nachweisen des Komplexes.

48. Verfahren zum Herstellen einer Zusammensetzung, die das KGF-Protein oder chimäres Protein gemäß einem der Ansprüche 1 - 14 oder 19 - 23 umfasst, wobei das Verfahren das Herstellen der Zusammensetzung in an sich bekannter Weise umfasst.

49. Verfahren zur Stimulierung des Epithelzellwachstums *in vitro*, wobei das Verfahren den Schritt des Hinzufügens einer für die Stimulierung des Epithelzellwachstums ausreichenden Menge der Zusammensetzung gemäß Anspruch 48 umfasst.

50. Verfahren gemäß Anspruch 49, worin die Zellen Keratinocyten sind.

#### Revendications

Revendications pour les Etats contractants suivants : AT, BE, CH, LI, DE, DK, FR, GB, IT, LU, NL, SE

1. Protéine de facteur de croissance des kératinocytes (KGF) isolée, glycosylée ou non glycosylée, comprenant : (a) la séquence d'acides aminés suivante, (b) une partie de la séquence d'acides aminés suivante sans les 31 acides aminés N-terminaux, ou (c) une séquence d'acides aminés qui diffère par l'addition, la délétion ou le remplacement d'un ou plusieurs acides aminés de la séquence d'acides aminés suivante :

MHKWILTWILPTLLYRSCFHIICL  
VGTISLACNDMTPEQMATNVNCS  
SPERHTRSVDYMEGGDIRVRLF

CRTQWYLRIDKRGKVKGTQEMK  
N  
NYNIMEIRTVAVGIVAIGVESEF  
YLAMNKEGKLYAKKECNEDCNFK  
ELILENHYNITYASAKWTHNGGEM  
FVALNQKGIPVRGKKTKEQKTA  
HFLPMAIT

ladite protéine étant capable de stimuler la synthèse d'ADN dans des kératinocytes épidermiques BALB/MK quiescents, par un facteur de plus de 500 x, tout en étant dépourvue d'activité mitogène sur les fibroblastes et les cellules endothéliales.

2. Protéine KGF de la revendication 1, dans laquelle 5 nM de ladite protéine manifestent une stimulation de moins de 1x par rapport à l'activité de fond dans des fibroblastes NIH/3T3.

3. Protéine KGF de la revendication 1 ou 2, qui a une activité spécifique d'au moins environ  $3,4 \times 10^4$  unités par milligramme de protéine, une unité d'activité étant définie comme la quantité qui provoque la moitié de la stimulation maximale possible de la synthèse d'ADN dans des kératinocytes BALB/MK.

4. Protéine KGF de l'une quelconque des revendications 1 à 3, qui est glycosylée.

5. Protéine KGF de l'une quelconque des revendications 1 à 3, qui n'est pas glycosylée.

6. Protéine KGF de l'une quelconque des revendications 1 à 5, comprenant la séquence d'acides aminés

CNDMTPEQMATNVNCS  
SPERHTRSVDYMEGGDIRVRLF  
CRTQWYLRIDKRGKVKGTQEMK  
N  
NYNIMEIRTVAVGIVAIGVESEF  
YLAMNKEGKLYAKKECNEDCNFK  
ELILENHYNITYASAKWTHNGGEM  
FVALNQKGIPVRGKKTKEQKTA  
HFLPMAIT

7. Protéine KGF de l'une quelconque des revendications 1 à 5, comprenant une séquence d'acides aminés différant par l'addition, la délétion ou le remplacement d'un ou plusieurs acides aminés de la séquence d'acides aminés suivante :

CNDMTPEQMATNVNCS  
SPERHTRSVDYMEGGDIRVRLF  
CRTQWYLRIDKRGKVKGTQEMK  
N  
NYNIMEIRTVAVGIVAIGVESEF  
YLAMNKEGKLYAKKECNEDCNFK  
ELILENHYNITYASAKWTHNGGEM



FVALNQKGIPVRGKKTKEQKTA  
HFLPMAIT

8. Protéine KGF de l'une quelconque des revendications 1 à 5, comprenant une séquence d'acides aminés différant par l'addition, la délétion ou le remplacement d'un ou plusieurs acides aminés de la séquence d'acides aminés suivante :

MHKWILTWILPTLLYRSCFHIICL 10  
VGTISLACNDMTPEQMATNVNCS  
SPERHTRS DYMEGGDIRVRLF  
CRTQWYLRI DKRGKVKG TQEMK  
N  
NYNIMEIRTVAVGIVAIGVSEF 15  
YLAMNKEGKLYAKKECNEDCNFK  
ELILENHYN TYASAKWTHNGGEM  
FVALNQKGIPVRGKKTKEQKTA  
HFLPMAIT.

9. Protéine KGF de l'une quelconque des revendications 1 à 5, comprenant un segment d'acides aminés de la figure II-1B, qui comprend les acides aminés 32 à 78 de la figure II-1B pour conférer à la protéine KGF une activité mitogène préférentielle sur une cellule épithéliale.

10. Protéine KGF de l'une quelconque des revendications 1 à 5, comprenant un segment de la séquence d'acides aminés suivante :

MHKWILTWILPTLLYRSCFHIICL  
VGTISLACNDMTPEQMATNVNCS  
SPERHTRS DYMEGGDIRVRLF  
CRTQWYLRI DKRGKVKG TQEMK 35  
N  
NYNIMEIRTVAVGIVAIGVSEF  
YLAMNKEGKLYAKKECNEDCNFK  
ELILENHYN TYASAKWTHNGGEM  
FVALNQKGIPVRGKKTKEQKTA 40  
HFLPMAIT.

11. Protéine KGF de la revendication 10, consistant en un segment de la séquence d'acides aminés suivante :

MHKWILTWILPTLLYRSCFHIICL  
VGTISLACNDMTPEQMATNVNCS  
SPERHTRS DYMEGGDIRVRLF 50  
CRTQWYLRI DKRGKVKG TQEMK  
N  
NYNIMEIRTVAVGIVAIGVSEF  
YLAMNKEGKLYAKKECNEDCNFK  
ELILENHYN TYASAKWTHNGGEM 55  
FVALNQKGIPVRGKKTKEQKTA  
HFLPMAIT.

12. Protéine de facteur de croissance des kératinocytes (KGF) glycosylé ou non glycosylé, isolé, selon l'une quelconque des revendications 1 à 5, consistant en un segment de la séquence d'acides aminés suivante :

CNDMTPEQMATNVNCS  
SPERHTRS DYMEGGDIRVRLF  
CRTQWYLRI DKRGKVKG TQEMK  
N  
NYNIMEIRTVAVGIVAIGVSEF  
YLAMNKEGKLYAKKECNEDCNFK  
ELILENHYN TYASAKWTHNGGEM  
FVALNQKGIPVRGKKTKEQKTA  
HFLPMAIT,

ledit segment ayant une activité mitogène pour un kératinocyte, et ledit segment pouvant comprendre en outre un résidu méthionine à l'extrémité aminoterminale.

13. Protéine KGF de la revendication 12 qui a une activité spécifique d'au moins environ  $3,4 \times 10^4$  unités par milligramme de protéine, une unité d'activité étant définie comme la quantité qui provoque la moitié de la stimulation maximale possible de la synthèse d'ADN dans des kératinocytes BALB/MK.

14. Protéine KGF de l'une quelconque des revendications 1 à 13, ladite protéine KGF comprenant Met à l'extrémité aminoterminale.

15. Composition pharmaceutique comprenant au moins une protéine KGF selon l'une quelconque des revendications 1 à 14.

16. Composition pharmaceutique comprenant au moins une protéine KGF selon l'une quelconque des revendications 1 à 14, pour la stimulation de cellules épithéliales.

17. Utilisation de la protéine KGF selon l'une quelconque des revendications 1 à 14, pour la fabrication d'un médicament pour la stimulation de cellules épithéliales.

18. Utilisation de la protéine KGF selon l'une quelconque des revendications 1 à 14, pour la fabrication d'un médicament, dans laquelle le médicament est destiné à être appliqué topiquement sur la peau ou sur l'oeil.

19. Utilisation selon la revendication 18, dans laquelle le médicament est destiné à être appliqué topiquement sur la peau.

20. Protéine chimère, comprenant dans une seule molécule de polypeptide une protéine KGF de l'une

quelconque des revendications 1 à 14 et au moins une autre partie polypeptidique de la famille des facteurs de croissance des fibroblastes.

21. Protéine chimère de la revendication 20, comprenant les aminoacides 32 à 78 de la figure II-1B, pour conférer à la molécule polypeptidique une activité mitogène préférentielle de KGF pour une cellule épithéliale. 5
22. Protéine chimère de la revendication 21, dans laquelle le facteur de croissance des fibroblastes est le facteur de croissance des fibroblastes acide (aFGF). 10
23. Protéine chimère de la revendication 22, dans laquelle la partie polypeptidique de aFGF est définie par les résidus aminoacides dans la partie de aFGF qui est homologue de la séquence de KGF responsable de la sensibilité de KGF à l'héparine. 20
24. Protéine chimère de la revendication 23, dans laquelle la protéine KGF est définie par les résidus aminoacides numérotés 32 à 78 sur la figure II-1B, et ladite partie polypeptidique de aFGF est définie par l'extrémité carboxy-terminale de aFGF, commençant avec le résidu numéro 39. 25
25. Composition pharmaceutique comprenant une protéine chimère selon l'une quelconque des revendications 20 à 24, et un véhicule pharmaceutiquement acceptable. 30
26. Utilisation d'une protéine chimère selon l'une quelconque des revendications 20 à 24, pour la fabrication d'un médicament destiné au traitement d'états nécessitant une stimulation spécifique de cellules épithéliales en présence d'héparine. 35
27. Utilisation d'une protéine chimère selon l'une quelconque des revendications 20 à 24, pour la fabrication d'un médicament qui est destiné à être appliqué topiquement sur la peau ou sur l'oeil. 40
28. Anticorps dirigé spécifiquement contre la protéine KGF de l'une quelconque des revendications 1 à 14. 45
29. Anticorps de la revendication 28, qui neutralise l'activité mitogène du KGF humain. 50
30. Anticorps de la revendication 28, qui est un anticorps polyclonal.
31. Anticorps de la revendication 28, qui est un anticorps monoclonal. 55
32. Anticorps de la revendication 28, qui réagit contre

le peptide NDMTPEQMATNVR.

33. Composition pharmaceutique comprenant au moins un anticorps de la revendication 28 et un véhicule pharmaceutiquement acceptable.
34. Utilisation de l'anticorps de l'une quelconque des revendications 28 à 32, pour la fabrication d'un médicament destiné à traiter des états nécessitant une inhibition spécifique de la stimulation de cellules épithéliales par le KGF.
35. Molécule d'ADN recombinant, codant pour un facteur de croissance des kératinocytes (KGF) selon l'une quelconque des revendications 1 à 14.
36. Molécule d'ADN recombinant, codant pour une protéine chimère selon l'une quelconque des revendications 20 à 24.
37. Molécule d'ADN recombinant comprenant l'ADN de la revendication 35 ou 36, et un vecteur.
38. Molécule d'ADN recombinant de la revendication 37, dans laquelle ledit vecteur est un plasmide, un vecteur de clonage de type bactériophage, un vecteur plasmidique de séquençage d'ADN, un vecteur d'expression de gène bactérien ou un vecteur d'expression de gène mammalien.
39. Cellule-hôte comprenant une molécule d'ADN recombinant de la revendication 37 ou 38.
40. Cellule de la revendication 39, dans laquelle ladite cellule est une cellule mammalienne, une cellule d'insecte, une cellule de levure ou une cellule bactérienne.
41. Procédé de production de la protéine KGF selon la revendication 1, comprenant la culture de la cellule de la revendication 39 ou 40, dans un milieu de culture, dans des conditions telles que ladite protéine est produite.
42. Procédé de la revendication 41, comprenant en outre l'isolement de la protéine KGF.
43. Procédé de la revendication 41, dans lequel ladite molécule d'ADN recombinant comprend un ADN promoteur autre que l'ADN promoteur pour le KGF natif, fonctionnellement lié à l'ADN codant pour la protéine KGF.
44. Procédé de la revendication 43, dans lequel ladite molécule d'ADN recombinant comprend de l'ADN natif codant pour la protéine KGF.
45. Procédé de l'une quelconque des revendications

41 à 44, dans lequel ladite cellule est une cellule de *E. coli*.

46. Procédé de production de la protéine ou protéine chimère KGF de l'une quelconque des revendications 1 à 14 ou 20 à 24, comprenant les étapes suivantes :

I) mise en contact d'une première solution, comprenant ladite protéine, avec de l'héparine, dans des conditions telles que ladite protéine se lie à l'héparine, ce par quoi un complexe héparine-protéine est formé ;  
 II) séparation dudit complexe héparine-protéine de ladite première solution ; et  
 III) dissociation de ladite protéine du complexe héparine-protéine.

47. Procédé pour la détermination du taux d'un transcrit d'ARN de KGF, comprenant les étapes suivantes :

I) isolement d'ARNm à partir de tissus ou de cellules ;  
 II) hybridation dudit ARNm avec une sonde d'ADN codant pour une protéine KGF selon l'une quelconque des revendications 1 à 14, pour la formation d'un hybride ADN:ARN ; et  
 III) détermination de la quantité dudit hybride ADN:ARN.

48. Procédé pour la détection d'une protéine KGF dans un échantillon, comprenant :

I) la mise en réaction de polypeptides provenant de liquides corporels ou d'échantillons de tissus, avec un anticorps de la revendication 29, pour la formation d'un complexe anticorps-polypeptide ; et  
 II) la détection dudit complexe.

49. Composition comprenant une protéine KGF ou protéine chimère de l'une quelconque des revendications 1 à 14 ou 20 à 24.

50. Procédé de stimulation de la croissance de cellules épithéliales in vitro, comprenant l'addition d'une quantité de la composition de la revendication 49, suffisante pour stimuler la croissance de cellules épithéliales.

51. Procédé de la revendication 50, dans lequel lesdites cellules sont des kératinocytes.

#### Revendications pour l'Etat contractant suivant : ES

1. Procédé pour la production d'une protéine de facteur de croissance des kératinocytes (KGF) isolée,

glycosylée ou non glycosylée, comprenant : (a) la séquence d'acides aminés suivante, (b) une partie de la séquence d'acides aminés suivante sans les 31 acides aminés N-terminaux, ou (c) une séquence d'acides aminés qui diffère par l'addition, la délétion ou le remplacement d'un ou plusieurs acides aminés de la séquence d'acides aminés suivante :

```
MHKWILTWILPTLLYRSCFHIICL
VGTISLACNDMTPEQMATNVNCS
SPERHTRS DYMEGGDIRVRRLF
CRTQWYLRIKRGKVKGTQEMK
N
NYNIMEIRTVAVGIVAIGVESEF
YLAMNKEGKLYAKKECNEDCNFK
ELILENHYN TYASAKWTHNGGEM
FVALNQKGIPVRGKKTKEQKTA
HFLPMAIT
```

ladite protéine étant capable de stimuler la synthèse d'ADN dans des kératinocytes épidermiques BALB/MK quiescents, par un facteur de plus de 500 x, tout en étant dépourvue d'activité mitogène sur les fibroblastes et les cellules endothéliales, comprenant la culture d'une cellule-hôte comprenant une molécule d'ADN recombinant codant pour ladite protéine KGF, dans des conditions telles que ladite protéine est produite.

2. Procédé de la revendication 1, dans laquelle 5 nM de ladite protéine manifestent une stimulation de moins de 1x par rapport à l'activité de fond dans des fibroblastes NIH/3T3.

3. Procédé de la revendication 1 ou 2, dans lequel la protéine KGF a une activité spécifique d'au moins environ  $3,4 \times 10^4$  unités par milligramme de protéine, une unité d'activité étant définie comme la quantité qui provoque la moitié de la stimulation maximale possible de la synthèse d'ADN dans des kératinocytes BALB/MK.

4. Procédé de l'une quelconque des revendications 1 à 3, dans lequel la protéine KGF est glycosylée.

5. Procédé de l'une quelconque des revendications 1 à 3, dans lequel la protéine KGF n'est pas glycosylée.

6. Procédé de l'une quelconque des revendications 1 à 5, dans lequel ladite protéine KGF comprend la séquence d'acides aminés

```
CNDMTPEQMATNVNCS
SPERHTRS DYMEGGDIRVRRLF
CRTQWYLRIKRGKVKGTQEMK
N
NYNIMEIRTVAVGIVAIGVESEF
```

YLAMNKEGKLYAKKECNEDCNFK  
ELILENHYN TYASAKWTHNGGEM  
FVALNQKGIPVRGKKTKEQKTA  
HFLPMAIT.

7. Procédé de l'une quelconque des revendications 1 à 5, dans lequel ladite protéine KGF comprend une séquence d'acides aminés différant par l'addition, la délétion ou le remplacement d'un ou plusieurs acides aminés de la séquence d'acides aminés suivante :

CNDMTPEQMATNVNCS  
SPERHTRS DYMEGGDIRVRRLF  
CRTQWYLRI DKGKVKGTQEMK  
N  
NYNIMEIRTVAVGIVAIGVSEF  
YLAMNKEGKLYAKKECNEDCNFK  
ELILENHYN TYASAKWTHNGGEM  
FVALNQKGIPVRGKKTKEQKTA  
HFLPMAIT

8. Procédé de l'une quelconque des revendications 1 à 5, dans lequel ladite protéine KGF comprend une séquence d'acides aminés différant par l'addition, la délétion ou le remplacement d'un ou plusieurs acides aminés de la séquence d'acides aminés suivante :

MHKWILTWILPTLLYRSCFHIICL  
VGTISLACNDMTPEQMATNVNCS  
SPERHTRS DYMEGGDIRVRRLF  
CRTQWYLRI DKGKVKGTQEMK  
N  
NYNIMEIRTVAVGIVAIGVSEF  
YLAMNKEGKLYAKKECNEDCNFK  
ELILENHYN TYASAKWTHNGGEM  
FVALNQKGIPVRGKKTKEQKTA  
HFLPMAIT

9. Procédé de l'une quelconque des revendications 1 à 5, dans lequel ladite protéine KGF comprend un segment d'acides aminés de la figure II-1B, qui comprend les acides aminés 32 à 78 de la figure II-1B pour conférer à la protéine KGF une activité mitogène préférentielle sur une cellule épithéliale.

10. Procédé de l'une quelconque des revendications 1 à 5, dans lequel ladite protéine KGF comprend un segment de la séquence d'acides aminés suivante :

MHKWILTWILPTLLYRSCFHIICL  
VGTISLACNDMTPEQMATNVNCS  
SPERHTRS DYMEGGDIRVRRLF  
CRTQWYLRI DKGKVKGTQEMK  
N  
NYNIMEIRTVAVGIVAIGVSEF  
YLAMNKEGKLYAKKECNEDCNFK  
ELILENHYN TYASAKWTHNGGEM  
FVALNQKGIPVRGKKTKEQKTA

HFLPMAIT.

11. Procédé de la revendication 10, dans lequel ladite protéine KGF consiste en un segment de la séquence d'acides aminés suivante :

MHKWILTWILPTLLYRSCFHIICL  
VGTISLACNDMTPEQMATNVNCS  
SPERHTRS DYMEGGDIRVRRLF  
CRTQWYLRI DKGKVKGTQEMK  
N  
NYNIMEIRTVAVGIVAIGVSEF  
YLAMNKEGKLYAKKECNEDCNFK  
ELILENHYN TYASAKWTHNGGEM  
FVALNQKGIPVRGKKTKEQKTA  
HFLPMAIT.

12. Procédé pour la production d'une protéine de facteur de croissance des kératinocytes (KGF) glycosylée ou non glycosylée, isolée, selon l'une quelconque des revendications 1 à 5, consistant en un segment de la séquence d'acides aminés suivante :

CNDMTPEQMATNVNCS  
SPERHTRS DYMEGGDIRVRRLF  
CRTQWYLRI DKGKVKGTQEMK  
N  
NYNIMEIRTVAVGIVAIGVSEF  
YLAMNKEGKLYAKKECNEDCNFK  
ELILENHYN TYASAKWTHNGGEM  
FVALNQKGIPVRGKKTKEQKTA  
HFLPMAIT.

ledit segment ayant une activité mitogène pour un kératinocyte, et ledit segment pouvant comprendre en outre un résidu méthionine à l'extrémité aminoterminal, comprenant la culture d'une cellule hôte comprenant une molécule d'ADN recombinant codant pour ladite protéine KGF, dans des conditions telles que ladite protéine est produite.

13. Procédé de la revendication 12, dans lequel ladite protéine KGF a une activité spécifique d'au moins environ  $3,4 \times 10^4$  unités par milligramme de protéine, une unité d'activité étant définie comme la quantité qui provoque la moitié de la stimulation maximale possible de la synthèse d'ADN dans des kératinocytes BALB/MK.

14. Procédé de l'une quelconque des revendications 1 à 13, dans lequel ladite protéine KGF comprend Met à l'extrémité aminoterminal.

15. Procédé pour la production d'une composition pharmaceutique comprenant au moins une protéine KGF selon l'une quelconque des revendications 1 à 14, comprenant la préparation de ladite

composition pharmaceutique, d'une façon connue en soi.

16. Procédé pour la production d'une composition pharmaceutique comprenant au moins une protéine KGF selon l'une quelconque des revendications 1 à 14, pour la stimulation de cellules épithéliales, comprenant la préparation de ladite composition pharmaceutique, d'une façon connue en soi.

17. Procédé pour la fabrication d'un médicament comprenant une protéine KGF selon l'une quelconque des revendications 1 à 14 dans lequel le médicament est destiné à être appliqué topiquement sur la peau ou sur l'oeil, comprenant la fabrication dudit médicament d'une façon connue en soi.

18. Procédé selon la revendication 17 dans lequel le médicament est destiné à être appliqué topiquement sur la peau.

19. Procédé pour la production d'une protéine chimère, dans lequel ladite protéine chimère comprend dans une seule molécule de polypeptide une protéine KGF de l'une quelconque des revendications 1 à 14 et au moins une autre partie polypeptidique de la famille des facteurs de croissance des fibroblastes, comprenant la culture d'une cellule-hôte, comprenant une molécule d'ADN recombinant codant pour ladite protéine chimère, dans des conditions telles que ladite protéine chimère est produite.

20. Procédé de la revendication 19, dans lequel ladite protéine chimère comprend les aminoacides 32 à 78 de la figure II-1B, pour conférer à la molécule polypeptidique une activité mitogène préférentielle de KGF pour une cellule épithéliale.

21. Procédé de la revendication 20, dans lequel le facteur de croissance des fibroblastes est le facteur de croissance des fibroblastes acide (aFGF).

22. Procédé de la revendication 21, dans lequel la partie polypeptidique de aFGF est définie par les résidus aminoacides dans la partie de aFGF qui est homologue de la séquence de KGF responsable de la sensibilité de KGF à l'héparine.

23. Procédé selon la revendication 22, dans lequel la protéine KGF est définie par les résidus aminoacides numérotés 32 à 78 sur la figure II-1B, et ladite partie polypeptidique de aFGF est définie par l'extrémité carboxy-terminale de aFGF, commençant avec le résidu numéro 39.

24. Procédé pour la préparation d'une composition pharmaceutique comprenant une protéine chimère

selon l'une quelconque des revendications 19 à 23, et un véhicule pharmaceutiquement acceptable, comprenant la préparation de ladite composition pharmaceutique d'une façon connue en soi.

25. Procédé pour la fabrication d'un médicament pour le traitement d'états nécessitant une stimulation spécifique de cellules épithéliales en présence d'héparine, dans lequel ledit médicament comprend une protéine chimère selon l'une quelconque des revendications 19 à 23, comprenant la fabrication dudit médicament d'une façon connue en soi.

26. Procédé pour la fabrication d'un médicament qui est destiné à être appliqué topiquement la peau ou sur l'oeil, dans lequel ledit médicament comprend une protéine chimère selon l'une quelconque des revendications 19 à 23, comprenant la fabrication dudit médicament d'une façon connue en soi.

27. Procédé pour la production d'un anticorps spécifiquement dirigé contre la protéine KGF de l'une quelconque des revendications 1 à 14, comprenant la culture d'une cellule-hôte comprenant une molécule d'ADN recombinant codant pour ledit anticorps, dans des conditions telles que ledit anticorps est produit.

28. Procédé de la revendication 27, dans lequel ledit anticorps neutralise l'activité mitogène du KGF humain.

29. Procédé de la revendication 27, dans lequel ledit anticorps est un anticorps polyclonal.

30. Procédé de la revendication 27, dans lequel ledit anticorps est un anticorps monoclonal.

31. Procédé de la revendication 27, dans lequel ledit anticorps réagit contre le peptide NDMTPEQMA-TNVR.

32. Procédé pour la préparation d'une composition pharmaceutique comprenant au moins un anticorps de la revendication 27 et un véhicule pharmaceutiquement acceptable, comprenant la préparation de ladite composition pharmaceutique d'une façon connue en soi.

33. Procédé pour la fabrication d'un médicament destiné au traitement d'états nécessitant une inhibition spécifique de la stimulation de cellules épithéliales par le KGF, dans lequel ledit médicament comprend l'anticorps de l'une quelconque des revendications 27 à 31, comprenant la fabrication dudit médicament d'une façon connue en soi.

34. Procédé pour la production d'une molécule d'ADN

recombinant, codant pour un facteur de croissance des kératinocytes (KGF) selon l'une quelconque des revendications 1 à 14, comprenant la construction de ladite molécule d'ADN recombinant d'une façon connue en soi.

35. Procédé pour la production d'une molécule d'ADN recombinant, codant pour une protéine chimère selon l'une quelconque des revendications 19 à 23, comprenant la construction de ladite molécule d'ADN recombinant, d'une façon connue en soi.
36. Procédé pour la production d'une molécule d'ADN recombinant comprenant l'ADN de la revendication 34 ou 35, et un vecteur, comprenant la construction de ladite molécule d'ADN recombinant, d'une façon connue en soi.
37. Procédé de la revendication 36, dans lequel ledit vecteur est un plasmide, un vecteur de clonage de type bactériophage, un vecteur plasmidique de séquençage d'ADN, un vecteur d'expression de gène bactérien ou un vecteur d'expression de gène mammalien.
38. Procédé pour la production d'une cellule-hôte comprenant une molécule d'ADN recombinant de la revendication 36 ou 37, comprenant la transformation d'une cellule-hôte par ladite molécule d'ADN recombinant.
39. Procédé de la revendication 38, dans lequel ladite cellule est une cellule mammalienne, une cellule d'insecte, une cellule de levure ou une cellule bactérienne.
40. Procédé de production de la protéine KGF selon la revendication 1, comprenant la culture de la cellule de la revendication 38 ou 39, dans un milieu de culture, dans des conditions telles que ladite protéine est produite.
41. Procédé de la revendication 40, comprenant en outre l'isolement de la protéine KGF.
42. Procédé de la revendication 40, dans lequel ladite molécule d'ADN recombinant comprend un ADN promoteur autre que l'ADN promoteur pour le KGF natif, fonctionnellement lié à l'ADN codant pour la protéine KGF.
43. Procédé de la revendication 42, dans lequel ladite molécule d'ADN recombinant comprend de l'ADN natif codant pour la protéine KGF.
44. Procédé de l'une quelconque des revendications 40 à 43, dans lequel ladite cellule est une cellule de *E. coli*.

45. Procédé de production de la protéine ou protéine chimère KGF de l'une quelconque des revendications 1 à 14 ou 19 à 23, comprenant les étapes suivantes :

- I) mise en contact d'une première solution, comprenant ladite protéine, avec de l'héparine, dans des conditions telles que ladite protéine se lie à l'héparine, ce par quoi un complexe héparine-protéine est formé ;
- II) séparation dudit complexe héparine-protéine de ladite première solution ; et
- III) dissociation de ladite protéine du complexe héparine-protéine.

46. Procédé pour la détermination du taux d'un transcrit d'ARN de KGF, comprenant les étapes suivantes :

- I) isolement d'ARNm à partir de tissus ou de cellules ;
- II) hybridation dudit ARNm avec une sonde d'ADN codant pour une protéine KGF selon l'une quelconque des revendications 1 à 14, pour la formation d'un hybride ADN:ARN ; et
- III) détermination de la quantité dudit hybride ADN:ARN.

47. Procédé pour la détection d'une protéine KGF dans un échantillon, comprenant :

- I) la mise en réaction de polypeptides provenant de liquides corporels ou d'échantillons de tissus, avec un anticorps de la revendication 28, pour la formation d'un complexe anticorps-polypeptide ; et
- II) la détection dudit complexe.

48. Procédé pour la préparation d'une composition comprenant la protéine ou protéine chimère KGF de l'une quelconque des revendications 1 à 14 ou 19 à 23, comprenant la préparation de ladite composition d'une façon connue en soi.

49. Procédé de stimulation de la croissance de cellules épithéliales *in vitro*, comprenant l'addition d'une quantité de la composition de la revendication 48, suffisante pour stimuler la croissance de cellules épithéliales.

50. Procédé de la revendication 49, dans lequel lesdites cellules sont des kératinocytes.




Figure I-1.




Figure I-2.






Figure I-3.




Figure I-4.




Figure I-5.

Table I-1. Growth Factor Purification.

Purification step	Protein (mg)	Total activity (units)	Specific activity (units/mg)
Conditioned medium (10 liters)	$1.4 \times 10^{3a}$	$2.5 \times 10^4$	$1.8 \times 10^1$
Ultrafiltration (retentate)	$1.3 \times 10^{3a}$	$3.2 \times 10^4$	$2.5 \times 10^1$
HSAC 0.6 M NaCl pool	$0.73^b$	$1.6 \times 10^4$	$2.2 \times 10^4$
TSX-G3000 SW	$8.4 \times 10^{-3b}$	$2.7 \times 10^3$	$3.2 \times 10^5$
C <sub>2</sub> -HPLC	$6.1 \times 10^{-3b}$	$2.1 \times 10^2$	$3.4 \times 10^6$

Tabl I-2. Target Cell Specificit. of Growth Factors

Growth Factor	Epithelial			Fibroblast	Endothelial
	BALB/3C	BS/589	CCL208	NIH/3T3S	Human saphenous vein
EGF	500-1000	2-3	5-10	<1	<1
EGF	100-200	20-40	10-30	10-20	n.d.
TGF $\alpha$	150-300	n.d.	n.d.	10-20	n.d.
aFGF <sup>a</sup>	300-500	2-3	5-10	50-70	5
bFGF	100-200	2-3	2-5	50-70	5





Figure II-1A.

**Figure II-1B.**

३३

[illegible]

Figure II-1C.






Figure II-2.

Figure II-3.






TABLE II-1. Effect of Heparin on KGF Mitogenic Activity.

<u>Growth Factor</u>	<u>SAH/TK</u>		<u>NIH/3T3</u>	
	•	•	•	•
KGF	150	9.5	<1	<1
aFGF	106	259	10.4	68
bFGF	30	124	45.7	70